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ABSTRACT
DESIGN AND SYNTHESIS OF POLYMERIC NANOPARTICLES FOR DRUG AND
PROTEIN DELIVERY
MAY 2015
JUDY VENTURA,
B. S., UNIVERSITY OF PUERTO RICO, MAYAGUEZ
Ph. D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sankaran Thayumanavan
Nanoparticles are emerging as carriers in biological applications due to advances in
their preparation, size control, surface modification and encapsulation capabilities. In
addition, nanomaterials improve bioavailability by enhancing aqueous solubility of the
guest molecule and increasing resistance time in the body. However, the delivery of
guest molecules is still challenging due to the intrinsic characteristics of the guest
molecule including large size and propensity to denature or degradation in the case of
biomolecules and the encapsulation stability of the small guest molecules.
Our group recently reported the preparation of self-cross-linked polymeric nanogels
possessing surface functionalization capabilities. In this dissertation we employed the
use of polymeric nanogels to explore and understand their guest encapsulation
capabilities with both hydrophilic and hydrophobic molecules. We were able to
encapsulate a protein in the hydrophobic core of the nanogels and recover is enzymatic
activity upon release. Moreover the surface of these nanogels can be also decorated with
surface exposed cysteine containing protein. We also reported a straightforward
methodology for the preparation of tri-functionalized amine materials with high
functional density.

	
  

vii	
  

TABLE OF CONTENTS
Page
ACKNOWLEDMENTS……………………………………………………………….....v
ABSTRACT……………………………………………………………………………..vii
LIST OF TABLES………………………………………………………………………..xi
LIST OF FIGURES……………………………………………………………………...xii
LIST OF SCHEMES………………………………………………………………….....xv
CHAPTER
1. INTRODUCTION: NANOPARTICLES AS CARRIERS…………………….............1
1.1 Introduction…………………………………………………………………...1
1.2 Nanoparticles for Drug Delivery………………………………………...........2
1.2.1 Characteristics of a Drug Delivery Carrier………………………….2
1.2.2 Redox Responsive Polymeric Nanoparticles…………………..........3
1.2.3 pH Responsive Polymeric Nanoparticles……………………………5
1.2.4 Light Responsive Polymeric Nanoparticles…………………………6
1.2.5 Temperature Responsive Polymeric Nanoparticles…………............7
1.3 Nanoparticles for Protein and Nucleic Acid Delivery………………...............8
1.3.1 Characteristics of a Biomolecule Carrier……………………………8
1.3.2 Protein Delivery………………………………………………..........9
1.3.2.1 Non-Covalent Protein-Nanocarrier Interactions……..........9
1.3.2.2 Covalent Protein-Nanocarrier Interactions………………10
1.3.3 Nucleic Acid Delivery……………………………………………..11
1.3.3.1 Cationic lipids…………..………………………..............12
1.3.3.2 Cationic Polymers………………………………………..13
1.4 Summary and Thesis Overview………………………………………….......15
1.5 References………………………………………………………………........15
2. STIMULUS-RESPONSIVE POLYMERIC NANOGELS SILENCE AND ALLOW
SELECTIVE REACTIVATION OF A SUICIDAL PROTEIN…………………………21
	
  

viii	
  

2.1 Introduction…………………………………………………………………..21
2.2 Results and Discussion………………………………………………............24
2.2.1 Preparation and Characterization of Nanogel-Caspase
Conjugates………………………………………………………………..24
2.2.2 Encapsulated Caspases are Active Upon Release………………….32
2.2.3 Nanogels Promote Cell Internalization…………………………….37
2.2.4 Caspase-Nanogel Assemblies Induce Apoptotic Cell Death………40
2.3 Summary……………………………………………………………………..43
2.4 Experimental Details…………………………………………………………44
2.4.1 Determination of the Number Accessible Cysteine………………..45
2.4.2 Labeling of Caspase……………………………………………......46
2.4.3 Synthesis of PEGMA-co-PDSMA…………………………………46
2.4.4 Synthesis of CRRR Peptide………………………………………..47
2.4.5 Synthesis of the Nanogel-Caspase Conjugates…………………….48
2.4.6

Crosslinking

Density,

Caspase

Conjugation

and

Peptide

Functionalization…………………………………………………………49
2.4.7 SDS-PAGE Studies………………………………………………...51
2.4.8 Enzymatic Degradation Experiment……………………………….51
2.4.9 Activity Assay……………………………………………………...52
2.4.10 Cell Internalization Studies…………………………………….....53
2.4.11 Apoptosis Studies………………………………………………...54
2.5 References……………………………………………………………………57
3. TRI-FUNCTIONALIZATION OF AMINE-BASED SCAFFOLDS UTILIZING AN
EPISULFIDE MOIETY………………………………………………………………….59
3.1 Introduction…………………………………………………………………..59
3.2 Results and Discussion………………………………………………………60
3.2.1 Scaffold Di-Functionalization and Characterization………………62
3.2.2 Scaffold Tri-Functionalization and Characterization……………...66
3.3 Summary……………………………………………………………………..68
3.4 Experimental Details………………………………………………………....68
3.4.1 Synthetic Protocols and Compounds Characterization…………….69

	
  

ix	
  

3.4.2 Control Experiment: Ellman’s Reagent Exposed to pH 8…….…...75
3.4.3 Control Experiment: Ellman’s Reagent exposed to 50oC………….74
3.5 References……………………………………………………………………74
4. EFFECT OF PARTITION COEFFICIENT IN DRUG LOADING AND
ENCAPSULATION EFFICIENCY IN POLYMERIC NANOGELS…………………..80
4.1 Introduction…………………………………………………………………..80
4.2 Molecular Design and Results……………………………………………….83
4.2.1 Pyrene and Perylene Spectral Overlap and Nanogel Sizes………...85
4.2.2 Encapsulation Efficiency Evaluation………………………………87
4.3 Summary……………………………………………………………………..92
4.4 References……………………………………………………………………92
5. SUMMARY AND FUTURE DIRECTIONS………………………………………....94
5.1 Summary……………………………………………………………………..94
5.2 Future Directions…………………………………………………………….95
BIBLIOGRAPHY………………………………………………………………………..97

	
  

x	
  

LIST OF TABLES
Table
Page
2.1 Summary of the properties of nanogels, caspase-3 and nanogel-caspase conjugates..27
2.2 Summary of the peptide sequences of caspase-3 detected by mass spectrometry…...31
4.1 Partition coefficient (log P) value for some drug molecules………………………...82
4.2 Validation of the Molinspiration software with literature values……………………85
4.3 Summary of the percentage of crosslinking density and encapsulation efficiencies...90

	
  

xi	
  

LIST OF FIGURES
Figure
Page
1.1 Cartoon representation of intracellular release of redox-responsive nanoparticles... 3
2.1 (A) DLS of nanogel-caspase conjugates (B) DLS of nanogel-caspaseRRR conjugates
(C) ζ-potential of nanogel-caspase conjugates (D) ζ-potential of nanogel-caspaseRRR
conjugates………………………………………………………………………………. 28
2.2 SDS-PAGE gel validating the nanogel-caspase conjugation through reducible
disulfide linkages. (A) Nanogel-caspase conjugates under non-reducing conditions. (B)
Nanogel-caspase conjugates under reducing conditions. (C) Nanogel-caspaseRRR
conjugates under non-reducing conditions. (D) Nanogel-caspaseRRR under reducing
conditions………………………………………………………………………………30
2.3 Mass spectra of (A) caspase-3 (B) NG-empty (C) NG-Casp In (D) NG-CaspOut………………………………………………………………………………………32
2.4 (A) Enzymatic activity of caspase-3 (B) caspase-3 percentage activity recovered
from nanogel-caspase conjugates (C) enzymatic activity of caspase-3 (D) percent activity
recovered from nanogel-caspase RRR conjugates………………………………………..34
2.5 SDS-PAGE gel validating the nanogel-caspase conjugation through reducible
disulfide linkages (A) Nanogel-caspasePEG conjugates under non-reducing conditions (B)
nanogel-caspasePEG conjugates under reducing conditions (C) percent activity recovered
from nanogel-caspasePEG conjugates…………………………………………………….36
2.6 Cellular internalization of the (A) NG-FITC-Casp-In (B) NG-FITC-Casp-Out (C)
NG-FITC-Casp-InRRR (D) NG-FITC-Casp-OutRRR at 0.5 mg/mL on HeLa cells……….39
2.7 Cell viability after 24 hours exposure of HeLa cells with the conjugates (A) nanogelcaspase conjugates (B) nanogel-caspaseRRR……………………………………………..42
2.8 Surface exposed cysteine residues in caspase-3……………………………………48
2.9 NMR spectrum of the CRRR peptide………………………………………………49
2.10 Absorption spectra of nanogel-caspase conjugate synthesis……………………….50
2.11 Activity of caspase-3 after an earlier construction protocol………………………..52
2.12 Caspase-3 cellular internalization…………………………………………………..53

	
  

xii	
  

2.13 Apoptosis experiment perfomed with nanogel-caspaseRRR on day two…………….54
3.1 Representation and chemical structures of the functionalities for the trifunctionalization process of amine-containing
scaffolds………………..………………………………………………………………...61
3.2 Absorption spectra of TNB to monitor the progress of the di-functionalization
reaction (A) nanoparticle (B) dendrimer………………………………………………...64
3.3 FTIR spectra of the di-functionalized (A) nanoparticle and (B) PPI dendrimer…….66
3.4 FTIR spectra of the tri-functionalized (A) nanoparticle and (B) PPI dendrimer…….67
3.5 Absorption spectra of tri-functionalized (A) nanoparticle and (B) dendrimer………67
3.6 1HNMR (A) and 13C NMR (B) of triethylene glycol mono methyl ether epoxide…..70
3.7 1HNMR (A) and 13C NMR (B) of triethylene glycol mono methyl ether episulfide...72
3.8 1HNMR spectrum of the Boc-AEMA-co-CPMA…………………………………....73
3.9 1HNMR spectrum of the deprotected AEMA-co-CPMA……………………………75
3.10 Absorption spectra of the Ellman’s reagent exposed to pH 8………………………75
3.11 Absorption spectra of the Ellman’s reagent in sodium phosphate buffer pH 8 at
50oC……………………………………………………………………………………...74
4.1 Potential FRET outcomes upon mixing nanogels independently encapsulating DiI and
DiO……………………………………………………………………..………………...81
4.2 (A) Synthesis of the nanogels intra- and inter-chain disulfide cross-linking of the PDS
groups in the presence of the reducing agent DTT (B) Molinspiration Interactive Log P
calculator…………………………………………………………………………………84
4.3 Chemical structure of the FRET pairs from each Log P value studied……………...84
4.4 (A) Absorption spectra of pyrene and perylene (B) Overlap spectra of FRET pairs
pyrene and perylene. Samples prepared at a concentration of 0.005 mg/mL in dimethyl
sulfoxide.……………………………………………………………………....................86
4.5 DLS of 0.1 mg/mL aqueous solution of nanogels encapsulating (A) pyrene and (B)
perylene…………………………………………………………………………………..87

	
  

xiii	
  

4.6 (A) Normalized emission spectrum of 5% crosslinked nanogels encapsulating 0.5
wt% pyrene. Concentration of the sample was 0.1 mg/mL (B) Absorption spectra of
different concentrations of pyrene and perylene in chloroform…………………………88
4.7 Calibration curve of (A) pyrene and (B) perylene in CHCl3 prepared to determine the
extinction coefficient for each dyes. Absorption spectra recorded of nanogels (0.1
mg/mL) with different crosslinking densities loading 0.5 wt% (C) pyrene and (D)
perylene. ………………………........................................................................................89
4.8 FRET evolution spectra of nanogels (A) 0% (B) 5% (C) 15% (D) 100% crosslinked.
Absorption spectra of nanogels (E) 0% (F) 5% (G) 15% (H) 100% crosslinked. These
measurements were taken at a concentration of 0.1 mg/mL …………………………….91

	
  
	
  

	
  

xiv	
  

LIST OF SCHEMES
Scheme
Page
1.1 Example of some pH labile crosslinkers………………………………………………6
1.2 Isomerization of azobenzene and salicylideneaniline…………………………………7
1.3 Chemical structure of poly(α-[4-amino-butyl]-L-glycolic acid) (PAGA) and poly(2aminoethyl propylene phosphate) (PPE-EA) used as neutral polymers for gene
delivery…………………………………………………………………………………..14
2.1 Covalent conjugation of caspase-3 in the interior or on the surface of polymeric redox
sensitive nanogels…………………………………………………………………..........24
3.1 Reaction of the 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) or Ellman’s reagent with
a thiol (R-SH)…………………………………………………………………………….62
3.2 Di-functionalization reaction of the (A) nanoparticle (B) PPI G4 dendrimer……….63
3.3 Synthesis of the triethylene glycol monomethyl ether episulfide……………………69
3.4 Synthesis of the Boc-AEMA-co-CPMA random copolymer………………………..73
3.5 Boc-deprotection of the AEMA-co-CPMA random copolymer……………………..74

	
  

xv	
  

CHAPTER 1
INTRODUCTION: NANOPARTICLES AS CARRIERS
1.1 Introduction
Nanotechnology is a field of study focused on the development of materials or devices
at a very small scale. These materials, often called nanoparticles, are defined as particles
with a size range from 1 to 100 nanometers in diameter. Nanomaterials have gained much
attention in the scientific community due to their small size, high surface area available
per unit volume and their ability to adsorb and carry other compounds.1–4 Nanoparticles
can be fabricated exhibiting morphological diversity such as spheres, hollow spheres,
cylinders, and disks among others.5–9 The surface of these materials can often be tailored
to meet the needs of a specific application. Moreover, their diverse chemical composition
including polymers, metals, biological, carbon and inorganic materials make them a
fundamental building block in nanotechnology applications.10–16
Advances in the preparation, size control, surface modification and encapsulation
capabilities of nanoparticles make them an ideal carrier for chemical drugs and
biomolecules. For instance, their inherent small size allows nanocarriers in the blood
stream to extravasate through the leaky tumor vasculature, which when combined with
impaired lymphatic drainage, contributes to the accumulation and retention of
nanocarriers in the diseased tissue.17 The delivery of nanoscopic carriers is greatly
influenced by the enhanced permeability and retention (EPR) effect. In order to achieve
targeting through the EPR effect, nanocarriers should exhibit sizes within the range of 10100 nm. Some organs, such as the kidneys, are capable of filtering positively charged
particles and can also remove particles smaller than 10 nm (~70 KDa) through renal
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clearance.18 Additionally, a majority of particles larger than 100 nm are taken up by the
liver or subjected to clearance by dendritic cells during circulation.18 Furthermore, the
surface of nanoparticles can be modified with affinity ligands such as antibodies,
aptamers and peptides that can recognize specific receptors on the cell surface.19–25 These
receptors should be overexpressed in the diseased cells but not on normal cells in order to
increase specificity.

Once the nanoparticles recognize and bind to the target cell,

internalization of the carriers is achieved by receptor-mediated endocytosis. During this
process, the cell engulfs the nanocarriers along with extracellular fluids through plasma
membrane invagination forming a membrane-bound vesicle or endosome. Nanocarriers
must escape endocytic organelles and reach the cytosol to release their contents before
being degraded by acidic pH or hydrolases in the endosomes. Various nanostructures
such as liposomes,26–28 carbon nanotubes,29,30 iron oxide nanoparticles,31–33 gold
nanoparticles,34,35 polymeric nanoparticles36–38 and dendrimers39,40 have been tested as
carriers in delivery systems. In this chapter we will discuss the use of polymeric
nanoparticles as carriers for delivery of (i) hydrophobic small drug molecules and, (ii)
hydrophilic biomolecules such as proteins and nucleic acids.

1.2 Nanoparticles for Drug Delivery
1.2.1 Characteristics of a Drug Delivery Carrier
Most of the drugs, especially anticancer drugs, are highly lipophilic, polar and
unstable in aqueous media undergoing less potent decomposition through hydrolysis.
Systemic administration of these small drugs can cause deleterious side effects since they
can diffuse across the cell membranes that are not the target of the drug. Therefore,
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researchers have been focusing on the development of polymeric materials that will help
to improve their solubility and to serve as carriers, in order to protect the drug during
circulation and release it under specific conditions. Polymeric drug carriers should (i) be
capable of encapsulating lipophilic drug molecules within their core, (ii) possess a
desirable size to achieve targeting through the EPR effect, (iii) stably encapsulate the
guest molecules to prevent premature release, (iv) release their contents in response to a
specific stimulus triggered by the target cell environment, (v) have an easily modified
surface for conjugation of targeting ligands, (vi) exhibit low inherent toxicity and (vii)
have reproducible synthetic methods. The following sections describe the different
stimuli that have been employed to prepare stimuli responsive nanoparticles.
1.2.2 Redox Responsive Polymeric Nanoparticles
Nanoscopic redox-responsive nanoparticles are particularly attractive because they
can be cleaved in the presence of high reducing agent concentrations such as reduced

Figure 1.1 Cartoon representation of intracellular release of redox-responsive
nanoparticles.
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glutathione (GSH) and thioredoxin.41–48 GSH is found at micromolar concentrations in
human plasma and about 10 mM in the cytosol of the cells.49 Interestingly, the
concentration of GSH in the cytosol of cancer cells is seven times higher than that
observed in normal cells.49 Therefore, development of delivery systems responsive to the
disulfide functionality by the act of GSH can facilitate intracellular release of
encapsulated drug molecules (Figure 1).
The disulfide functionality can be located into the backbone or side groups of the
polymeric carriers and the drug molecule can be encapsulated or covalently attached to
the polymeric carriers. In addition, the disulfide bond can also be located at the
connection of two polymer blocks. A commonly employed strategy is the use of
amphiphilic polymers containing disulfide functionality within their hydrophobic
backbone for the preparation of self-assembled micelles. In the presence of GSH, the
micelles will disassemble due to the loss of amphiphilic character resulting in the release
of the cargo. Zhou et al. prepared a polymer micelle system containing sheddable
polyethylenimine (PEI) shells that are deshielded upon cleavage of the disulfide bonds
from the core of the micelles.50 The drug molecule, in this case doxorubicin, is then
released into the cytoplasm of the cell. Our group has also reported the preparation of
micellar aggregates from the self-assembly of amphiphilic polymer composed of
triethylene glycol and an alkyl chain as the hydrophobic part connected to the backbone
of the polymer by a disulfide bond.49 Other reports employ the use of redox responsive
crosslinking moieties on the core or the shell of micellar aggregates resulting in rapid
disassembly of the micelle upon their reduction. Cheng et al. prepared crosslinked core
micelles

	
  

from

a

biodegradable

amphiphilic

4	
  

block

copolymer,

monomethoxy

poly(ethylene glycol)-b-poly(Tyr(alkynyl)-OCA).51 The micelles, prepared with a redoxresponsive crosslinker in the core showed responsiveness towards reducing agents
resulting in their disruption and subsequent release of the cargo. Our group has developed
a delivery platform that involves the use of self-crosslinked nanogels composed of an
amphiphilic random copolymer containing oligoethylene glycol and pyridyldisulfide
(PDS) units as side chain functionalities.52 These nanogels were developed based on the
collapse and self cross-linking of a limited number of PDS side chain groups. Upon their
reduction, guest molecules such as doxorubicin are released intracellularly facilitating the
internalization of hydrophobic guest molecules.
1.2.3 pH Responsive Polymeric Nanoparticles
Environmental stimuli such as pH gradient have also been employed to trigger
changes in the properties of polymeric materials. For example, at the organ level, delivery
systems have been designed to respond to the differences in the pH of the gastrointestinal
tract. The stomach lumen for digestion has a pH between 1-3, the duodenum ~5, the
jejunum ~6 and ileum 6.6 – 7.5.53–55 A commonly employed approach to achieve drug
release in the gastric tract is the use of acrylic-based polymers.

At low pH these

polymers retain their collapse state. An increase in the pH results in the swelling of the
nanoparticle due to the protonation of the carboxylic groups and loss of hydrogen
bonds.56 At the tissue level, the extracellular environment of solid tumors is more acidic
(pH 6.5) than that for normal cells (pH 7.4) due to the lactic acid accumulation.57 A
strategy employed is to utilize these pH differences to induce hydrophobic-hydrophilic
transitions of the polymer.

This transition culminates with the disruption of the

nanoparticles due to the loss of hydrophobic-hydrophilic balance. β-amino ester-

	
  

5	
  

containing polymers are commonly employed since at pH below 6.5 the protonation of
the amine converts the polymer from hydrophobic to hydrophilic.58,59 Targeting acid
responsiveness at the cellular level can also be achieved through the pH value of
compartments, such as early endosome and lysosomes decreasing to values of 5.0 or
lower.60 Amine-containing polymers such as polyethylenimine, poly(amidoamine) and
imidazole containing polymers that buffer the pH of intracellular compartments have
been commonly used to improve endosomal escape.61 Scheme 1.1 illustrates some pH
labile crosslinkers.

R

N
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H
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R''
R

Hydrazone

R'
O

O

Orthoester

O
N

R

Imine

R'

R

O

S

R''

B-Thiopropionate

Scheme 1.1 Example of some pH labile crosslinkers.

1.2.4 Light Responsive Polymeric Nanoparticles
Light is another stimulus utilized to induce phase transition in polymers and
subsequent collapse of the carriers. To achieve light responsiveness, photochromic
moieties are incorporated into the structure of the polymeric nanoparticles.

These

molecules or chromophores undergo photo-induced structural changes resulting in an
increase in the polarity (water solubility) of the block. Cyclization, structural
isomerization or ring opening are some of the transformations of the moieties upon
irradiation at a certain wavelength. Azobenzene is a chromophore commonly employed
due to its rapid trans-to-cis photoisomerization upon irradiation.62,63 This isomerization
causes an increase in the dipole moment and on the lower critical solution temperature
(LCST) of the molecule.62,63 Salicylideneaniline is another molecule that undergoes
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isomerization from the enol to the trans-keto form upon irradiation with UV light
(Scheme 1.2).64 Spiropyran and fulgimides are photochromic molecules that undergo
photoisomerization as well.65 Coumarin and ortho-nitrobenzyl groups are also molecules
whose structures change. For example coumarins can crosslink after photochemical
driven [2 + 2] addition reaction and ortho-nitrobenzyl groups cleave upon light
irradiation.66
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Scheme 1.2 Isomerization of azobenzene and salicylideneaniline.

1.2.5 Temperature Responsive Polymeric Nanoparticles
Changes in the solubility, conformation and hydrophobic-hydrophilic balance of
polymers can be achieved by variations in temperature. For instance, poly(N-isopropyl
acrylamide) (PNIPAM) below its LCST (32oC) exist as an expanded coil in a swollen
hydrate.67 Upon heating the polymer shrinks, collapsing into a globular state and
becoming more hydrophobic.68 Poly(dimethylamino)ethyl methacrylate (PDMA) possess
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a LCST between 40-50oC and along with ethylene glycol-based polymers undergo
hydrophilic-to-hydrophobic phase transitions.69 Another property utilized to prepare
thermoresponsive materials is the upper critical solution temperature (UCST) that
represents the temperature at which the components of a mixture are miscible in all
proportions. Polyoxazolines and polysulfobetaines are common materials showing UCST
and used as temperature-responsive materials.
1.3 Nanoparticles for Protein and Nucleic Acid Delivery
1.3.1 Characteristics of a Biomolecule Carrier
Delivery of functional biomolecules such as proteins, siRNA and DNA are gaining
interest in the scientific community having potential applications in cancer, stem cell
engineering and genetic disorders. This is due mostly to the possibility of correcting
disorders by artificially incorporating a gene and replacing poorly expressed or
dysfunctional proteins in the cellular machinery. However, the delivery of such
hydrophilic biomolecules is challenging and limited due to their propensity to denature,
delicate structure and large size among other reasons. During the preparation and
development of delivery systems, it is important to keep in mind that carriers should be
capable of protecting the cargo molecule from enzymatic degradation and efficiently
translocate it to the cytoplasm or nucleus of the cell, depending on the site of action for
the cargo molecule. Another important aspect of the carrier is the capability to protect
and deliver the biomolecule in an active conformation. In the following sections we will
briefly discuss current approaches employed for the delivery of such biomolecules.
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1.3.2 Protein Delivery
The delivery of proteins can be classified into two categories; non-covalent and
covalent protein interaction with the nanocarrier.
1.3.2.1 Non-Covalent Protein-Nanocarrier Interactions
Electrostatic assembly or hydrophilic and hydrophobic interactions are non-covalent
strategies employed to conjugate proteins to polymeric nanocarriers. Proteins can be
physically adsorbed by electrostatic forces on the surfaces of polymeric vehicles. For
instance, Akiyoshi et al. prepared self-assembled cationic nanogels composed of
cholesteryl group-bearing pullulans.70 These nanogels interacted strongly with two
proteins of opposite charge, bovine serum albumin (BSA) and β-galactosidase (β-gal).
This formed monodispersed nanoparticles <50 nm. The nanogel-protein complexes were
effectively internalized by HeLa cells and the protein was release after cellular uptake.
Similarly, in another report from Yang et al. the preparation of cationic nanoparticles
from an amphiphilic copolymer poly{(N-methyldietheneamine sebacate)-co-[(cholesteryl
oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate} was
described.71 These polymers self-assembled and a glycoprotein, lectin A-chain, was
bound on the surface of the nanoparticles. Size was determined to be about 150 nm by
dynamic light scattering and the zeta potential was 30 mV. The cytotoxic effect of
delivering lectin A-chain was assessed in different cancer cells showing to be effective in
inducing cell death. A similar approach was developed in our group where nanogels were
prepared from amphiphilic copolymer containing oligo(ethylene glycol) methacrylate and
pyridyldisulfide methacrylate.72 These nanogels were functionalized with tri-arginine, a
cell penetrating peptide providing a cationic character to the surface of the nanocarriers.
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β-galactosidase was complexed with the nanogels by complementary electrostatic
interactions and an X-gal activity assay demonstrated that the protein retains its activity
upon cellular entry.
1.3.2.2 Covalent Protein-Nanocarrier Interactions
Proteins are commonly conjugated to polymeric materials by covalent interactions
utilizing the surface exposed lysine and/or non-disulfide bonded cysteine residues. Other
functional groups can be employed to tether proteins to nanocarriers such as hydroxyl,
carboxylic acids. Park and co-workers prepared glucose coated polymeric beads using 6O-glucosyl methacrylate, styrene and acrylic acid.73 Enhanced green fluorescent protein
(EGFP) was conjugated to the beads by the acrylic acid monomer and (1-ethyl-3-(3dimethylaminopropyl)carbodiimide) (EDC) coupling. Fluorescence microscopy showed
cellular internalization of conjugated EGFP glucose-coated beads into mouse embryonic
stem (mES) and HeLa cells. Polyethylenimine (PEI) is a polymer widely tested in vitro
and in vivo applications in different fields. Hughes et al. utilized PEI to conjugate
phospholipase A2 (PLA2) and to accomplish this they utilized also utilized EDC
coupling.74 They demonstrated that the conjugate retained PLA2 activity by measuring
the enzymatic activity of the protein after adding the substrate, dhiheptanoyl thio-PC. The
consumption of the substrate yielded a yellow color product that was monitored by
recording the absorption spectra at 405 nm.
In 2013, our group reported the covalent conjugation of BSA to polymeric nanogels
composed of poly(ethylene glycol) methacrylate and pyridyl disulfide (PDS)
methacrylate.75 Protein-nanogel conjugation was achieved through disulfide linkages.
BSA contains one non-disulfide bonded cysteine residue but in this case, it was not
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accessible for conjugation with remaining PDS from the nanogels. Therefore, the protein
was modified with N-succinimidyl S-acetylthiopropionate and then deprotected to expose
a thiol group. This modified-protein was then successfully conjugated to the polymeric
nanogels. Finally, Maynard et al. prepared protein-polymer conjugates by polymerization
of N-isopropylacrylamide (NIPAAM) and protein macroinitiators.76 The initiators were
prepared by reacting free cysteines from BSA and T4 lysozyme V131C and then with
initiators for atom transfer radical polymerization (ATRP). Enzymatic activity
demonstrated that lysozyme was unaffected by the polymerization conditions and
polymer conjugation.
1.3.3 Nucleic Acid Delivery
Introduction of nucleic acid such as DNA or RNA to replace a defective gene or to
manipulate the function/expression of a gene are avenues under investigation with
implications in genetic diseases. The high molecular weight and persistence length of
nucleic acid prevent them from crossing the negatively charged lipid bilayer.
Furthermore, delivery of naked DNA often results in their degradation by proteases and
rapid clearance culminating in low levels of transfection. Therefore, a delivery system
capable of crossing the lipid bilayer, escape the endosome and release the nucleic acid
into the nucleus is essential. There are two vectors commonly employed by researchers;
viral and non-viral vectors. Viral vectors are very efficient at introducing foreign nucleic
acid into the cells machinery however, their use has brought safety concerns about the
potential to cause severe immune and inflammatory responses. Non-viral methods are
considered to have low pathogenicity but their transfection efficiency is low. In addition,
viral vectors are difficult to produce in large scale. Consequently, non-viral methods are
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still preferred over viral methods representing a powerful tool in gene therapy. In this
category, two classes of materials have received great attention: cationic lipids and
cationic polymers.
1.3.3.1 Cationic Lipids
Cationic lipids and liposomes are used as vectors due to their ability to condense
nucleic acid through complementary opposite charges. Their lipidic nature allows them to
achieve high transfection efficiencies. Some of the commonly used cationic lipids
include:

2,3-dioleyloxy-N-[2-spermine

carboxamide]

ethyl-N,N-dimethyl-1-

propanammonium trifluoroacetate (DOSPA, Lipofectamine), N-[1-(2,3-dimyristyloxy)
propyl]-N,N-dimethyl-N-(2-hydroxyethyl)

ammonium

bromide

(DMRIE),

imethyldioctadecylammonium bromide (DDAB), and diotadecyl amidoglyceryl spermine
(DOGS,Transfectam) among others (Scheme 1.3). In 2011, Lee and colleagues prepared
cationic

lipoplexes

from

1,2-Di-O-octadecenyl-3-trimethylammonium

propane

(DOTMA), D-Alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS)
and cholesterol.77 DOTMA was chosen as a component of the miRNA delivery system
due to its high transfection efficiency. TPGS was utilized to increase the stability and
cholesterol was employed as a helper lipid to increase transfection potency. The
lipoplexes achieved higher transfection efficiencies and 50-fold higher accumulation in
the lungs when compared to siPORT NeoFX transfection agent. In another report, Fattal
et al. described the preparation of cationic lipoplexes composed of [2-(2,3didodecyloxypropyl)hydroxyethyl]ammonium

bromide

(DE)

and

dioleoylphosphatidylethanolamine (DOPE) and plasmid pCMV-luc.78 A hyaluronic acid
(HA) conjugate, HA-DOPE, was prepared and introduced to the DE-DOPE liposomes to
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target the CD44 receptor present on breast cancer cells. The transfection efficiency of
lipoplexes containing HA-DOPE increased on cancer cell expressing the CD44 receptor
when compared to plain polyplexes. Despite the advances in the use of cationic lipids as
vectors, it is important to keep in mind that different structural aspects of the lipids such
as head group size and hydrophobic tail length can have a different impact on the
transfection efficiency, cell internalization and toxicity. Improvements to these delivery
vectors are constantly under investigation to fit the needs of the gene to be delivered, cell
type, environment and application.
1.3.3.2 Cationic Polymers
Cationic polymers are gaining interest as nucleic acid vectors due to their ease of
tuning structural features to achieve targeting capabilities and biocompatibility. In
addition, facile synthesis, robustness and the stability of the polymer-nucleic acid
complex make them attractive in gene therapy. Poly-L-lysine (PLL), polyethylenimine
(PEI) and polyamidoamine dendrimers (PAMAM) are a few examples of commonly and
extensively studied polymers. As cationic lipids, cationic polymers operate on the same
fundamental principle; condensing nucleic acid based in charge complementarity.
However, their transfection efficiency is still lower than that for viral vectors. During the
last decade, a number of studies have emerged with new designs of polymers for gene
delivery. For example, Part et al. developed a non-toxic polymeric gene carrier by using a
biodegradable PLL analogue called poly(α-[4-amino-butyl]-L-glycolic acid) (PAGA)
(Scheme 1.3).79 This polymer was synthesized by converting the α –amino group of ε–
cbz-L-lysine to a hydroxyl group. They demonstrated that this polymer was able to
condense plasmid DNA forming nanoparticles of about 326 nm. Moreover, this polymer
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showed higher transfection efficiencies than PLL and while being non-toxic.
Polyphosphoester is another polymer that has been utilized as a gene carrier. In 2001, a
group reported the preparation of biodegradable poly(2-aminoethyl propylene phosphate)
(PPE-EA) consisting of a phosphoester backbone and aminoethoxy as the side chain.80
After plasmid DNA complexation, the DNA remained intact following exposure of the
polyplexes to DNase I. As PAGA, PPE-EA showed higher transfection efficiency than
PLL in the presence of chloroquine.
Neutral polymers can also be employed as gene delivery carriers.

These non-

condensing polymers interact with the nucleic acid by hydrogen bonding and/or van der
Waals interactions.

Some of these polymers include: polyvinylpyrolidone (PVP),

polyvinyl alcohol (PVA) and poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol)b-poly(D,L-lactic-co-glycolic acid) (PLGA-PEG-PLGA).81 These polymers can facilitate
cellular uptake protecting the DNA from degradation.

O
P
O
O

O
O
n

H 3N

O
n

Cl

H 2N

PAGA

PPE-EA

Scheme 1.3 Chemical structure of poly(α-[4-aminobutyl]-L-glycolic acid) (PAGA) and poly(2-aminoethyl
propylene phosphate) (PPE-EA) used as neutral
polymers for gene delivery.
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1.4 Summary and Thesis Overview
In this chapter, we discussed the use of polymeric nanoparticles as carriers to
encapsulate hydrophobic drug molecules and biomolecules such as nucleic acid and
proteins. We also described various stimuli employed as triggers to induce the release or
disassembly of these polymeric nanoparticles.
In this dissertation we describe the design and synthesis of polymeric nanogels for
drug and protein delivery applications. We also describe a methodology to trifunctionalize polymeric nanoparticles. In the upcoming chapters we discuss (i) the
silencing of an apoptosis inducing protein through protein-polymer conjugation in
Chapter 2, (ii) the methodology to multi-functionalized polymeric nanoparticles in
Chapter 3, (iii) the effect of the hydrophobicity or log P of the guest molecule in the
encapsulation stability in Chapter 4, (iv) the summary of the thesis and future directions.
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CHAPTER 2
STIMULUS-RESPONSIVE POLYMERIC NANOGELS SILENCE AND ALLOW
SELECTIVE REACTIVATION OF A SUICIDAL PROTEIN

2.1 Introduction
Proteins perform vital biological functions, ranging from gene regulation1-2 to
catalysis of metabolic reactions3-4 and cell signaling5-6 to programmed cell death.7-9
Proteins are widely used as therapeutics because they often exhibit higher specificity and
offer more nuanced functions than can be achieved by small synthetic drugs.10-12
Unfortunately, many of the most biologically important proteins have inherent liabilites
for manipulation and direct administration, including complications such as tremendous
flexibility and a metastable “folded” state, large size, propensity to aggregate and
susceptibility to oxidation or degradation. As a result, the development of proteinpolymer nanoconjugates to stabilize and deliver proteins is gaining tremendous
interest.13-16 Traditionally, conjugation of proteins to polymeric nanocarriers has been
quite challenging due to the propensity of proteins to denature during polymer
conjugation, which often requires using organic solvents and harsh synthesis
conditions.17-18
During the past decade researchers have explored different approaches for conjugating
proteins to telechelic, branched, star polymers and polymeric supramolecular molecules
without compromising the activity or integrity of the protein.19-25 A commonly employed
approach is the covalent conjugation of polymeric reactive side chains with surface
exposed residues such as lysines and non-disulfide bonded cysteines.26-27 Since proteins
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may contain more than one reactive residue exposed to the solvent or have poor
accesibility, there is little control over the conjugation site. To circumvent this,
researchers have developed genetically modified proteins containing a single cysteine or
lysine residue available for conjugation,28 but such modifications may have significant
implications on the stability or function of the protein. Inverse microemulsion methods1718, 29-31

are also commonly employed where the protein, monomer, and crosslinker in the

aqueous phase are dispersed in the organic phase and polymerization is carried out
around the protein. Meanwhile, controlled radical polymerization (CRP) methods are
also gaining popularity and emerging as a powerful tool among researchers where
proteins are modified with a moiety capable of chain initiation.32-35 Despite this, exposure
to organic/aqueous phases and separation of unreacted protein or monomer can still be
challenging, compromising protein integrity. Self-assembly between polymeric
nanoparticles and proteins is utilized as an alternative method to prevent irreversible
chemical modification of proteins. Depending on surface charge, proteins can also be
physically adsorbed by electrostatic forces onto the surface of polymeric vehicles.36-39
The next challenge in this area is protecting proteins during delivery to prevent
modification or inactivation. This is particularly applicable in biological milieu, such as
blood, where proteins can be degraded by proteases, oxidized or subjected to a number of
other insults. The goal of this work was to develop polymeric nanogels that are capable of
protecting and delivering large, highly mobile, aggregation prone and enzymatically
challenging proteins intracellularly. Caspases are one such class of targets.
Caspases are cysteine proteases that are known for their exquisite specificity for
cleaving after particular aspartic acid residues and rapidly inducing apoptotic cell
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death.40-43 Their ability to trigger apoptosis makes them promising for selective cell
killing, especially in cancer therapeutics. Among the family of apoptotic caspases,
caspase-3 is of particular interest due to its major role in cleaving substrates during
apoptosis as well as its high catalytic rate.44 Caspase-3 also presents five surface-exposed
cysteine residues in each monomer (Figure 2.8) which can be utilized as handles for
attachment to polymeric materials using thiol chemistry. Conjugation of caspases to
polymeric materials is particularly attractive since it harnesses a cell’s own biological
processes to induce cell death. However, transport of active caspases can be dangerous as
release in an erroneous location can lead to irreversible proteolytic damage or even
unwanted apoptotic death. The therapeutic potential of caspases for inducing cell death
could be harnessed if it were possible to silence caspase activity through polymer
conjugation and then recover its activity upon response to a precise trigger.
Our group recently reported self cross-linked polymeric nanogels and demonstrated
the capability of these vehicles to stably encapsulate hydrophobic molecules and release
them in response to a specific stimulus.45-47 However, no such strategy exists for
hydrophilic molecules such as proteins. We envisioned developing a self-crosslinking
based strategy to encapsulate proteins using similar polymers, where the redox responsive
characteristics of the polymer will be utilized to first silence and later activate the
encapsulated proteins. In this chapter, we explored whether thiol-disulfide exchange
reactions would be capable of silencing the enzymatic activity of a caspase, protecting the
protein from denaturation during synthesis and delivery, and finally enabling intracellular
delivery of an active caspase with the nanogel vehicles. We report the preparation of
polymeric nanogels to which caspase-3 was reproducibly conjugated either in the interior
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or on the nanogel surface through disulfide linkages (Scheme 2.1). These nanogelcaspase conjugates were further functionalized with a cell penetrating peptide and the
enzymatic activity of the protein was evaluated upon dissociation from the nanogels.

Scheme 2.1. Covalent conjugation of caspase-3 in the interior or on the surface of
polymeric redox sensitive nanogels.

2.2 Results and Discussion
2.2.2 Preparation and characterization of nanogel-caspase conjugates
In order to form nanogels appropriate for conjugation and transport of hydrophilic
cargos, it was essential to carefully design the polymer. The random copolymer nanogel
precursor was obtained by the reversible addition-fragmentation chain transfer (RAFT)
polymerization of oligo(ethylene glycol) (OEG) methacrylate and pyridyldisulfide (PDS)
methacrylate. The feed ratio of the monomer was 50:50 and experimentally the resulting
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copolymer was found to contain 48% of the OEG units and 52% of the PDS groups as
discerned by NMR (Figure 2.9). In aqueous solution, this amphiphilic polymer forms
micelle-like aggregates; these aggregates were locked using a self-crosslinking process.
This self-crosslinking process was enabled by intra- and inter-chain disulfide crosslinking of the PDS groups in the presence of the reducing agent dithiothreitol (DTT).
The nanogel formation process was monitored by tracing the absorption spectra of
pyridothione (byproduct of the disulfide crosslinking) at 343 nm (Figure 2.10). Based on
the pyridothione released, the crosslink density of these nanogels was 18% (Figure
2.10A). These nanogels were labeled as ‘NG-empty’, since these do not have any cargo
molecules encapsulated inside. We then investigated the possibility of localizing and
attaching the protein to the nanogel: either encapsulated within the crosslinked nanogel
structure or decorated on the nanogel surface. To encapsulate caspase-3 within the
interior, caspase-3 and the amphiphilic polymer were added simultaneously to aqueous
media. As a result, caspase-3 was sequestered in the core of the micellar aggregates
during the self-assembly process of the polymer. The protein was then “locked-in” the
assembly by initiating thiol-disulfide exchange reactions between PDS groups with
addition of DTT, trapping caspase-3 within the core of these nanogels (Scheme 2.1, NGCasp-In). It is likely that the exposed cysteines on the caspase also played a role in the
efficient encapsulation of the proteins within the nanogel. To take advantage of the
surface conjugation capabilities of these polymeric materials, we first prepared the crosslinked nanogels (NG-empty) and caspase-3 was then covalently attached on its surface
using the cysteine residues of the protein and unreacted PDS groups (Scheme 2.1, NG-
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Casp-Out).

This effectively decorated the nanogel with caspase-3 attached on the

outside.
Due to their hydrophobic nature, we expected that unreacted PDS groups might
collapse into the core of the nanogels, but found that we could still achieve surface
functionalization of these nanogels with reasonable efficiency. We also prepared
nanogels with cell penetrating capabilities by incorporating a cysteine-containing triarginine peptide48-49 on the surface of these nanogels to generate NG-EmptyRRR, NGCasp-InRRR, NG-Casp-OutRRR (Scheme 2.1). Incorporation of the peptide on the surface
was confirmed by further increase in the pyridothione absorption spectra (Figure 2.10D,
E and F). Based on the pyridothione released, we found that the presence or absence of
caspase had no overall impact in the ability to conjugate a second molecular entity. Also,
the crosslinking densities of these nanogels NG-EmptyRRR, NG-Casp-InRRR, NG-CaspOutRRR were each found to be 18%.
To further characterize these nanogel-protein conjugates, we evaluated their size by
dynamic light scattering (DLS) and found that the hydrodynamic diameter of free
caspase-3, NG-Empty and NG-EmptyRRR were 6, 12, and 10 nm respectively (Figure
2.1). After the conjugation of caspase to the nanogels, there was an increase in the size of
the conjugates, indicative of protein conjugation (12 nm – 18 nm, Figure 1A and B). At
pH 7.4, caspase-3 is negatively charged (pI value of 6.09), whereas CRRR is highly
positively charged due to the arginine residues. These differences led us to evaluate the
change in the surface charge of these conjugates by zeta potential measurements. After
conjugation of caspase-3, the surface charge of NG-Casp-In (-19 mV) did not change
significantly from the value observed in the original NG-Empty (-17 mV, Figure 1C). In
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the case of NG-Casp-Out, the zeta potential value obtained shifted towards -7 mV,
similar to the value observed for free caspase-3 (-8 mV). After surface decoration of
nanogels with CRRR, we expected that NG-EmptyRRR would show a positive zeta
potential value since these nanogels do not have caspase-3 conjugated. As expected, the
surface charge for NG-EmptyRRR was found to be +18 mV. However, with caspase-3
conjugation, the surface charge became less positive: +4 mV for NG-Casp-InRRR and +9
mV for NG-Casp-OutRRR (Figure 2.1D). These results, along with the UV-vis absorption
spectra recorded during the nanogel-caspase conjugates synthesis (Figure 2.10, 2.11),
suggest that unreacted PDS groups from the nanogels were sterically available to
covalently react with the surface exposed cysteine residues from caspase-3. Furthermore,
despite the presence of a large and bulky biomacromolecule on these polymeric nanogels,
subsequent surface functionalization by CRRR addition can also be achieved,
demonstrating the prevalent accessibility and reactivity of the PDS groups. The properties
of these nanogel-caspase conjugates are summarized in Table 2.1.

Table 2.1. Summary of the Properties of Nanogels, Caspase3 and Nanogel-Caspase Conjugates.
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Figure 2.1 (A) DLS of nanogel-caspase conjugates (B) DLS of nanogel-caspaseRRR
conjugates (C) ζ-potential of nanogel-caspase conjugates (D) ζ-potential of
nanogel-caspaseRRR conjugates.

To further assess the protein conjugation to the nanogels, we utilized sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) to assess caspase dissociation
from the nanogels in a reducing environment (Figure 2.2). When treated with SDS,
caspase-3 dissociates into the constituent large and small subunits (17 and 12 kDa,
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respectively), which migrate as two characteristic bands on SDS-PAGE. We expected
that caspase-3 covalently conjugated to the inside or outside of nanogels should not be
observable by SDS-PAGE, because it will remain bound to and migrate (or fail to
migrate) with the nanogel. We expected to observe the two caspase-3 bands only after
treatment of the nanogels with a reducing agent. As anticipated, we did not observe the
bands corresponding to caspase-3 in the NG-Casp-In nor NG-Casp-Out samples in the
absence of reductant (Figure 2.2A). This suggests that caspase-3 is covalently conjugated
through disulfide bonds and not simply associated through physical adsorption. Since
disulfide bonds can be cleaved in the presence of high reducing agent concentrations, we
hypothesized that we should be able to “unlock” the protein from the assembly by
exposing the conjugates to DTT. The appearance of the characteristic caspase-3 bands for
the large and small subunits in both samples, NG-Casp-In and NG-Casp-Out, indicated
that the protein was released after the reduction of disulfide bonds. This confirmed the
conjugation of caspase-3 in both the “in” and “out” configurations (Figure 2.2B) and
demonstrated that these nanogels respond to a specific redox stimulus, namely DTT. We
estimated the concentration of caspase-3 released from each conjugate by comparing the
intensity of the bands from nanogel-released caspase to known concentrations loaded into
neighboring wells. Both nanogel-caspase conjugates (50 µg) released about 2 µg of
caspase-3. Similar results were observed for the nanogels functionalized with the cellpenetrating peptide, RRR. Under non-reducing conditions, no caspase bands were
observed for the NG-Casp-InRRR and NG-Casp-OutRRR samples (Figure 2.2C). When the
samples were exposed to reducing conditions, we observed the appearance of the bands
indicative of free caspase-3 released from NG-Casp-InRRR and NG-Casp-OutRRR (Figure
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2.2D). The concentration of released caspase-3 from 50 µg NG-Casp-InRRR and NGCasp-OutRRR was found to be 1 µg and 0.5 µg, respectively.

	
  
Figure 2.2. SDS-PAGE gel validating the nanogel-caspase conjugation through
reducible disulfide linkages. (A) Nanogel-caspase conjugates under non-reducing
conditions. (B) Nanogel-caspase conjugates under reducing conditions. (C) NanogelcaspaseRRR conjugates under non-reducing conditions. (D) Nanogel-caspaseRRR under
reducing conditions.

A capability that we wish to demonstrate here is that the proteins can be encapsulated
within the interior of these nanogels or conjugated to the surface of the nanogels by
simply altering the order of protein conjugation and crosslinking steps. Therefore, to
determine if the caspase-3 was indeed predictably conjugated in the interior or on the
surface of the nanogels we performed an enzymatic degradation study. The conjugates
were exposed to acetonitrile (20% of the total volume) to denature the protein. A protein
digest was then conducted by the addition of trypsin, a serine protease that hydrolyzes
peptide bonds strictly after the basic residues arginine and lysine.50 These fragments were
then analyzed by mass spectrometry (MS). First, caspase-3 itself was subjected to the
trypsin treatment conditions and the MS analysis displayed 7 major peaks with m/z values
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of 1018.5238, 1118.5436, 1617.8265, 1764.9102, 1854.8610, 1933.8967 and 1963.9908
(Figure 3.3A). The caspase-3 fragments that each of these peaks represent are shown in
Table 2.2.
Table 2.2. Summary of the Peptide Sequences of Caspase-3
Detected by Mass Spectrometry

	
  
We also analyzed empty nanogels by the same method; as expected, no peaks were
observed in the mass spectrum (Figure 3.3B).

In the case of the NG-Casp-In, we

expected that if the caspase-3 was in fact encapsulated within the crosslinked core of the
assembly, trypsin would not be able to reach the caspase-3 and therefore no signal would
be observed. As predicted, none of the peaks observed previously for caspase-3 were
present, suggesting that the protein is “locked-in” and protected from proteolytic
digestion within the nanogels (Figure 3.3C). On the other hand, in the case of NG-CaspOut, peaks with m/z matching those observed for caspase-3 were detected, demonstrating
that these caspase molecules are indeed on the outside of the nanogel assemblies and not
protected from proteolysis like those in the NG-Casp-In state (Figure 3.3D). These results
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demonstrate the versatility of these polymeric materials to covalently bind proteins and
“cage” the cargo protein within the nanogel, protecting it from enzymatic degradation.
2.2.2 Encapsulated caspases are active upon release.
An attractive aspect of this system is the versatility of these polymeric nanogels to be
decorated either at the surface with cargo proteins or to “wrap-up” intact active cargo

Figure 2.3 Mass spectra of (A) caspase-3 (B) NG-Empty (C) NG-Casp-In (D) NGCasp-Out.
proteins, and then release this cargo in response to a redox trigger. This capability is only
useful if protein cargos retain enzymatic activity upon release from the nanogels. The
enzymatic activities of caspase-3 conjugated to the nanogels or released after redox
stimulus were assessed using a fluorogenic substrate cleavage assay.

Based on

quantification of caspase-release (Figure 2.2), the activity from the precise quantity of
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nanogels encapsulating 50 nM caspase-3 was measured under non-reducing conditions
(Figure 2.4). Due to the fact that the catalytic cysteine of caspase-3 requires a reducing
environment to be active, a small amount of DTT (0.5 mM) was added for the “nonreducing conditions.” This was enough reductant to assess activity of any unbound
caspase, but not enough to promote disassembly of the nanogels. Under these conditions,
none of the conjugates exhibited caspase-3 activity, suggesting there is no unbound active
caspase and the enzyme conjugated to the nanogel is effectively catalytically silenced.
This silencing could be due to the structural constraints imposed by the nanogels and/or
the lack of accessibility to the peptide substrate. The fact that no caspase-substrate
cleavage was observed, even in the NG-Casp-Out nanogels, suggests that even nonencapsulated caspase have been catalytically silenced. Caspase-3 contains a free and
highly-reactive cysteine at its surface that is part of its catalytic diad (Cys-285). Due to its
reactivity, it is likely that this cysteine could be one of the primary amino acids to be
conjugated to the nanogel.

Thus, in the case of surface incorporated caspase, the

protein’s observed activity could be silent due to covalent conjugation of the active site
Cys-285.
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Figure 2.4 (A) Enzymatic activity of caspase-3 (B) caspase-3 percentage activity recovered
from nanogel-caspase conjugates was measured under essentially non-reducing (0.5 mM
DTT) or fully-reducing (100 mM DTT) conditions. At 0.5 mM DTT no disassembly of
nanogels is observed, whereas at 100 mM DTT full disassembly is observed (C) enzymatic
activity of caspase-3 (D) percent activity recovered from nanogel-caspase RRR conjugates.
This experiment was performed in duplicate on each of two days.	
  	
  

The nanogel-caspase conjugates were then incubated in the presence of 100 mM DTT
to release the caspase-3 cargo. Activity was observed after incubation with 100 mM
DTT, confirming that the protein is active upon release from the nanogel (Figure 2.4A
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and C). Released caspase-3 activity reached 17% (Figure 2.4B) upon release from NGCasp-In and NG-Casp-Out and 74% for NG-Casp-InRRR and NG-Casp-OutRRR (Figure
2.4D). An earlier protocol for the construction of caspase-containing nanogels utilized
lyophilization. Caspase-3 is an obligate heterotetramer, which does not refold
spontaneously with high yields, so it is not surprising that dramatically lower yields of
functional protein (0.24-3%) were released from lyophilized nanogels using the older
protocol (Figure 2.11). Given the 15-74% recovery rates observed currently, it is safe to
conclude that the conjugation process itself is mild and that the nanogels protect the
caspase, helping it to avoid denaturation and thus retain enzymatic activity. We were
surprised to note the higher fraction of recovered caspase-3 activity upon release from the
triarginine-containing nanogels, NG-Casp-InRRR and NG-Casp-OutRRR (Figure 2.4D) than
from NG-Casp-In and NG-Casp-Out (Figure 2.4B). This result was puzzling, since both
these types of nanogels had very similar abilities to induce cellular apoptosis (vide infra).
A key difference between these nanogels is that the non-functionalized nanogels (NGCasp-In, NG-Casp-Out) contain unreacted PDS moieties, while these functional groups
have been consumed during conjugation of the RRR peptide in the functionalized
nanogels (NG-Casp-InRRR and NG-Casp-OutRRR). We hypothesized that during release
from the non-functionalized nanogels that the added DTT is initially increasing the
percent crosslinking (toward 100%) leaving only a remaining fraction of DTT to liberate
the caspase from what is then a much more extensively crosslinked nanogel. To test this
hypothesis, we prepared the non-functionalized nanogel-conjugates as before, with an
18% crosslinking density and then reacted away the remaining PDS groups using thiolterminated PEG (MW 1k) to generate NG-Casp-InPEG and NG-Casp-OutPEG. Next, the
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enzymatic activity of capase-3 was assessed after exposing the conjugates to 100 mM
DTT. SDS-PAGE of the nanogel-caspase PEG-thiol conjugates validated the caspase
conjugation (Figure 2.5A and B). Once the non-functionalized nanogel-conjugates were
protected from additional crosslinking by the addition of PEG groups, it was possible to
release and recover a high percentage of caspase activity (79% and 86%, Figure 2.5C)
comparable to those observed for the nanogel-caspaseRRR conjugates. The extent of

	
  
Figure 2.5 SDS-PAGE gel validating the nanogel-caspase conjugation through
reducible disulfide linkages (A) Nanogel-caspasePEG conjugates under non-reducing
conditions (B) nanogel-caspasePEG conjugates under reducing conditions (C) percent
activity recovered from nanogel-caspasePEG conjugates.
recovered caspase-3 activity is quite remarkable considering the lability of the caspase
heterotetramer and its dependence on proper formation of the active-site loop bundle for
activity. This high yield indicates that these nanogels incorporate their cargo without
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damaging it, while at the same time remaining robust and responding specifically to a
redox stimulus.
2.2.3 Nanogels promote cell internalization
The ultimate goal for the use of these nanogel-protein conjugates is deliver enzymes in
their inactive form and activate them using the innate intracellular environment in
mammalian cells. In this case, such caspase delivery is expected to result in cell killing.
To determine whether caspase-conjugated nanogels are capable of internalization in
living cells, we monitored the cellular uptake of nanogels upon incubation of the
conjugates with HeLa cells. Caspase-3 was labeled with fluorescein isothiocyanate
(FITC) to enable intracellular visualization; the cell nucleus was stained with DRAQ5.
The fluorescence distribution of FITC and DRAQ5 was observed by confocal
fluorescence microscopy (Figure 2.6, 2.12). FITC-caspase-3 was observed for nanogels
caspase on the surface or inside of nanogels (Figure 2.6A, B), whereas no fluorescence
was visible in cells treated with FITC-labeled caspase-3 (Figure 2.12), suggesting that the
protein is not capable of penetrating the cells by itself and requires nanogel conjugation
for efficient internalization. Cellular uptake of nanogel conjugates is slow. This trend
mirrors previous reports showing no significant internalization of related nanogels at
doses of 0.1 mg/mL after 6 hours in HeLa cells.51 To improve uptake, triarginine
containing peptides were also incorporated into caspase-containing nanogels (NG-CaspOutRRR and NG-Casp-InRRR; Scheme 2.1) As predicted, nanogels functionalized with
RRR displayed higher accumulation of caspase-3 both on the membrane and in the cell
within this short time frame. This is likely due to the increased local concentration of the
positively charged RRR and the negatively charged cellular membrane. Although there
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is no clear consensus as to the detailed mechanism by which the RRR-targeted
assemblies are internalized, it is now widely accepted that arginine-rich peptides and their
cargo are internalized via endocytosis.52-54
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Figure 2.6 Cellular internalization of the (A) NG-FITC-Casp-In (B) NG-FITC-Casp-Out
(C) NG-FITC-Casp-InRRR (D) NG-FITC-Casp-OutRRR at 0.5 mg/mL on HeLa cells. Within
each image set, top left is the FITC channel, which show green color for caspase-3 and top
right is the DRAQ5 channel, which shows red color for the nucleus. Bottom left is the DIC
image and bottom right is the overlap of all three. This experiment was performed with
triplicate visualization on one day. One representative field is shown for each condition.
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2.2.4 Caspase-nanogel assemblies induce apoptotic cell death
Caspase-3 plays a critical role during the apoptotic process, so we anticipated strong
cell death-inducing potential of these nanogel-caspase conjugates, which release up to
75% of the caspase-3 cargo in an active form. The extent of cell death was measured in
HeLa cells treated with increasing doses of the nanogel conjugates (Figure 2.7).
Staurosporine, a protein kinase inhibitor known to induce apoptosis55 was used as a
positive control. After 24 hours, cell viability was measured using Alamar Blue assay.
Apoptosis is characterized by the marked changes in cell morphology such as cell
shrinkage and blebbing.56 HeLa cells treated with nanogel caspase conjugates appear to
be rounded and shrinking similar to as those undergoing apoptosis induced by
staurosporine (Figure 2.11), suggesting that killing was via an apoptotic route.
We anticipated that bare nanogels would be relatively non-toxic and that those
conjugated to caspase-3 should exhibit higher rates of cell death induction. NG-Empty
exhibited low cellular toxicity at concentrations up to 1 mg/mL (Figure 2.7A), whereas
nanogel-caspase conjugates displayed a strong dose response for cell death.

At a

concentration of 1 mg/mL, the cell viability for both NG-Casp-In and NG-Casp-Out was
reduced to nearly 20%. To confirm that the cell death observed in the nanogel-caspase
conjugates was induced by the intracellular release of active caspase-3 aided by the
nanogels and not by the action of caspase-3 in solution, cells were exposed to free
caspase-3 utilizing the amount of protein fed during the synthesis of 0.1 mg/mL, 0.5
mg/mL and 1 mg/mL nanogels (50:1 weight ratio, nanogel:caspase-3). Since caspase-3
alone is not expected to effectively penetrate the cell membrane, we anticipated that the
protein itself should not induce cell death. As expected, the cell viability observed for
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caspase-3 was approximately 80% for a concentration up to 1 mg/mL, indicating that the
vast majority of the cell death observed corresponded to apoptosis induced by the
intracellular release of active caspase-3 from the polymeric nanogels. Similar results
were observed for the case of nanogels decorated with RRR peptide (Figure 2.7B). At a
concentration of 1 mg/mL, the cell viability for NG-EmptyRRR was about 80% (Figure
2.7B); this may be because positively charged RRR peptides directly penetrate the cell
membrane, causing rupture or damage, thus introducing higher toxicity.57 Similar to the
nonfunctionalized nanogel caspase conjugates, the RRR nanogels induced cell death in a
dose responsive manner. Cell viability for NG-Casp-InRRR and NG-Casp-OutRRR was
about 30-35% at a concentration up to 1 mg/mL.

Although nanogels lacking any

targeting peptides (Figures 2.6A, B) show much less cell internalization than the RRR
nanogels, they are more capable of inducing cell death. At first this result was perplexing,
with cell internalization studies seemingly uncorrelated with increases in cell death.
However, upon further investigation we observed that that the RRR-decorated nanogels
appear to be accumulating on cell membranes, rather than being fully incorporated in the
cytoplasm where caspases can be released and activated.58 In particular, cationic cell
penetrating peptides are known to enter cells via endocytosis.52-54 If indeed these
nanogels are getting trapped in an endosome, they would be unable to release their cargo
due to the oxidizing environment of this cell compartment.59-60 Even if the nanogel was
disrupted, the oxidizing conditions and endosomal pH would render the caspase inactive.
Caspase-3 is optimally active at pH 7.5 with a significant decrease in activity at pH
values in the endosome (estimated to be from 5 to 6.5)61-62 dropping to just 10%
remaining activity at pH 6.0.63 Thus, although far fewer NG-Casp exist in cells and NG-
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CaspRRR are more abundant overall, the NG-Casp have greater cell-killing potential,
presumably due to their more favorable intracellular localization. This points to an

Figure 2.7 Cell viability after 24 hours exposure of HeLa cells with the conjugates (A)
nanogel-caspase conjugates (B) nanogel-caspaseRRR. * The concentration in the caspase-3
samples is the feed amount of caspase-3 used when preparing 0.1 mg/mL, 0.5 mg/mL and
1 mg/mL solutions. Nanogel:Caspase-3 (50:1). The experiment of figure 7A was
performed in triplicate on one day. The experiment in figure 7B was performed in
triplicate on two separate days. Data from one day is shown. The second day is Figure
2.13.
	
  

important finding. Optimal delivery of caspase will utilize a non-endocytic pathway or
will require delivery materials capable of endosomal escape. The fact that the nanogels
(without the cell penetrating peptides) exhibit excellent apoptotic efficiency suggests that
these nanocarriers are already doing well. Future generations of caspase-containing
nanogels that utilize alternate targeting ligands that are capable of cytosolic delivery,
rather than the triarginine peptides, which are known to accumulate in the endosome,
should yield even more productive delivery systems, capable of selective cell killing via
apoptosis at even lower doses.
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2.3 Summary
In this chapter we report here robust strategies to conjugate active enzymes to
polymeric nanogels with responsive characteristics, where caspase-3 has been used as the
active protein cargo. In this study, we show that: (i) the proteins can be attached to the
surface of the nanogels or can be encapsulated within the polymeric nanogel. (ii) The
activity of the protein is completely turned off in both these approaches, a feature that is
useful when delivering cargos that could have deleterious consequences in off-target
locations. (iii) The redox sensitive unlocking event causes the protein to be reactivated,
allowing recovery of ~80% of the activity. In addition to showing the versatility of these
approaches, the fact that these have been demonstrated with a protein that is very prone to
irreversible unfolding suggests that this approach is broadly applicable to other proteins.
(iv) The recovery of activity under reducing conditions can be capitalized inside cells,
where the reducing environment of the cytosol due to high glutathione concentrations is
targeted as the triggering mechanism. This was discerned by the fact that both
conjugation approaches provide robust cellular entry, protein release, and apoptotic
activity. (v) The nanogel-protein conjugate was able to gain cellular entry, while the
protein by itself did not enter the cells. These results, combined with the fact that the
nanogel by itself is not cytotoxic, suggest that these conjugates are promising protein
carriers. (vi) The protein conjugated to the surface of the nanogel is prone to proteolysis,
while the encapsulated protein is not accessible to proteolytic enzymes. These results
suggest that while both approaches are versatile for in vitro protein delivery, the
encapsulation approach is more promising for future in vivo applications. (vii) The
nanogel-protein conjugates, decorated with cell-penetrating peptides, gain cellular entry
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much more rapidly compared to the unfunctionalized nanogels. However, the overall
apoptotic efficiency of the unfunctionalized nanogels is comparable (or even better than)
to those functionalized with RRR. These results show that the unfunctionalized nanogels
end up in the cytosol more effectively, as these are not complicated by electrostatic
association with cellular membranes. The fact that the unfunctionalized nanogels are
slow in cellular uptake, but are more effective in releasing the cargo, bodes well for
utilizing these vehicles for targeted delivery of other protein cargos. These efforts are
currently underway in our laboratories.
2.4 Experimental Details
Polyethylene glycol monomethyl ether methacrylate (PEGMA) (MW 475), 2,2′dithiodipyridine,

2,2′-azobis(2-methylpropionitrile)

(AIBN),

4-cyano-4-

(phenylcarbonothioylthio) pentanoic acid (chain transfer agent), D,L-dithiothreitol
(DTT), and other conventional reagents were obtained from commercial sources and
were used without further purification, except for AIBN which was purified by
recrystallization. Pyridyl disulfide ethyl methacrylate (PDSMA) was prepared using the
previously reported procedure (Macromolecules, 2006, 39, 5595-5597). 1H-NMR spectra
were recorded on a 400 MHz Bruker NMR spectrometer using the residual proton
resonance of the solvent as the internal standard. Chemical shifts are reported in parts per
million (ppm).

Molecular weight of the polymer was estimated by gel permeation

chromatography (GPC) in THF using the poly(methyl methacrylate) (PMMA) standard
with a refractive index detector. Dynamic light scattering (DLS) measurements were
performed using a Malvern Nanozetasizer. UV-Visible absorption spectra were recorded
on a Varian (Model EL 01125047) spectrophotometer. Size exclusion chromatography
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was performed on Amersham Biosciences chromatography system equipped with a GE
health care life sciences superdex 75 10/300 GL column. Activity assay was performed
utilizing Spectramax M5 spectrophotometer. MALDI-MS analyses were performed on a
Bruker Autoflex III time-of-flight mass spectrometer. All mass spectra were acquired in
the reflectron mode, and an average of 200 laser shots at an optimized power (60%) was
used. Cell imaging was performed using Zeiss 510 META confocal microscope.
2.4.1, Determination of the number of accessible and reactive cysteine (thiols) on
caspase-3.
A 1.5 mL stock of 10 µM caspase-3 was purified using a NAP25 (GE Healthcare) size
exclusion column to fully exchange the buffer to 20 mM Tris pH 8.0 and eliminate all
DTT. The caspase-3 (3.6 µM) was then incubated at room temperature with 50 µM of
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) for 30 minutes. The absorbance of this
reaction was then recorded at 412 nm. The Beer-Lambert law was then used on the
corrected absorbance with a molar absorptivity for DTNB of 14,150 M-1cm-1 and a path
length of 1 cm. This yielded 5 DTNB molecules per monomer of caspase, indicating that
there are 5 accessible and reactive cysteine thiols per monomer of caspase-3.
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Figure 2.8 Surface exposed cysteine residues in caspase-3

	
  
2.4.2 Labeling of Caspase-3 with FITC
Fluorescein isothiocyanate isomer I (FITC) was dissolved in a 100 mM sodium
bicarbonate solution pH 9.0 to a concentration of 1 mg/mL. Caspase-3 (2.65 mg) was
diluted to 2 mL in 100 mM sodium bicarbonate buffer pH 9.0 with a total of 1.5 mg of
FITC present. This reaction was protected from light and allowed to stir overnight at 4°C.
The resulting FITC-labeled caspase-3 was dialyzed in 50 mM Tris pH 7.5, 50 mM NaCl,
and 2 mM DTT to remove excess FITC. The caspase was then concentrated using a 3k
Da spin filter and the concentration was measured by UV-vis absorption spectroscopy.
2.4.3. Synthesis of p(PEGMA-co-PDSMA) (P1)
A mixture of PDSMA (536.8 mg, 2.1 mmol), PEGMA (1 g, 2.1 mmol), 4-Cyano-4(phenylcarbonothioylthio) pentanoic acid (21 mg, 0.0756 mmol) and AIBN (1.2 mg,
0.00756 mmol) were dissolved in 3 mL THF in a 10 mL Schlenk flask and degassed by
performing three freeze-pump-thaw cycles with an argon inflow into the reaction. The
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reaction vessel was sealed and placed in a pre-heated oil bath at 70°C for 12 hours. The
product polymer P1 was then purified by precipitation in cold ether (20 mL) to yield the
random copolymer. Yield: 90%. GPC (THF) Mn: 20 K. Đ: 1.5. 1H-NMR (400 MHz,
CDCl3) δ: 8.45, 7.66, 7.09, 4.20-4.06, 3.80-3.42, 3.01, 2.10-1.65, 1.10-0.80. The molar
ratios between the two blocks was determined by the integration of the methoxy proton in
the polyethylene glycol unit and the aromatic proton in the pyridine and found to be
48%:52% (PEG:PDS).
2.4.4. Synthesis of CRRR peptide
This peptide was prepared following a previously reported procedure (J. Am. Chem.
Soc., 2012, 134, 6964-6967) except utilizing a different resin. Rink Amide AM resin
(200-400 mesh) was selected as the solid support to prepare the peptide using the solid
phase synthesis. Peptide was used without further purification.

1

H NMR (400 MHz,

D2O) δ: 4.45-4.52, 4.30-4.41, 4.03-4.11, 3.15-3.26, 2.92-3.01, 1.73-1.96, 1.55-1.96. MS
(FAB): exact mass calculated: 590.7. Found: 590.0

Figure 2.9 NMR spectrum of the CRRR peptide
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2.4.5 Synthesis of the nanogel-caspase conjugates
The nanogels were prepared as follows. NG Empty: The polymer (3 mg) was
dissolved in 1mL 1X PBS buffer pH 7.4 and the solution was left stirring at 20°C for 15
minutes. A measured amount of DTT was added to the micellar aggregates and the
solution was allowed to crosslink for 1 hour at 20°C. The resulting nanogels were
dialyzed at 20°C using a 7000 MWCO membrane. NG-Casp-In: The polymer (3 mg)
was dissolved in 1mL 1X PBS buffer pH 7.4 and the solution was left stirring at 20°C for
15 minutes. To this micellar aggregate solution, 0.06 mg of caspase-3 was added and the
mixture was left reacting for 1 hour at 20°C. A measured amount of DTT was added to
the solution and was stirred for another hour at 20°C to allow for crosslinking. The
resulting nanogels were dialyzed at 20°C using a 7K MWCO membrane and unbound
caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100,000. NG-CaspOut: The polymer (3 mg) was dissolved in 1mL PBS buffer pH 7.4 and the solution was
left stirring at 20°C for 15 minutes. A measured amount of DTT was added to the
micellar aggregates and the solution was allowed to crosslink for 1 hour at 20°C. Then,
0.06 mg of caspase-3 was added and the mixture was left reacting for another hour at
20°C. The resulting nanogels were dialyzed at 20°C using a 7K MWCO membrane and
unbound caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100,000.
NG EmptyRRR: To functionalize the surface of the nanogels, the same procedure described
above for nanogels was followed. In addition, an excess of the ligand (5 mg), CRRR,
was added and then stirred for another hour at 20°C. The resulting nanogels were
dialyzed at 20°C using a 7K MWCO membrane. NG-Casp-InRRR: To functionalize the
surface of the nanogels, the same procedure described above for NG-Casp-In was

	
  

48	
  

followed. In addition, an excess of the ligand (5 mg), CRRR, was added and then stirred
for another hour at 20°C. The resulting nanogels were dialyzed at 20°C using a 7K
MWCO membrane and unbound caspase-3 was removed by Amicon Ultra Centrifugal
Filters MWCO 100,000. NG-Casp-OutRRR: To functionalize the surface of the nanogels,
the same procedure described above for NG-Casp-Out was followed. In addition, an
excess of the ligand (5 mg), CRRR, was added and then stirred for another hour at 20°C.
The resulting nanogels were dialyzed at 20°C using a 7K MWCO membrane and
unbound caspase-3 was removed by Amicon Ultra Centrifugal Filters MWCO 100,000.
2.4.6 Crosslinking density, caspase conjugation and peptide functionalization
The crosslinking density was determined following the reported procedure (J. Am.
Chem. Soc., 2012, 134, 6964-6967) by calculating the amount of the byproduct,
pyridothione, and its known molar extinction coefficient (8.08 x 103 M-1 cm-1 at 343 nm)
(Bioconjugate Chem. 2006, 17, 1376-1384). The functionalization of the nanogels with
CRRR peptide was evaluated by the further formation of pyridothione (increase in the
absorption spectra at 343 nm).
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Figure 2.10 Absorption spectra of nanogel-caspase conjugates synthesis. A) NG Empty
(0.1 mg/mL) B) NG-FITC-Casp-In (0.1 mg/mL) C) NG-FITC-Casp-Out (0.1 mg/mL) D)
NG EmptyRRR (0.05 mg/mL) E) NG-FITC-Casp-InRRR (0.05 mg/mL) F) NG-FITC-CaspOutRRR (0.05 mg/mL)
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2.4.7 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
studies
Samples of NG-Empty (50 µg), NG-Casp-In (50 µg), NG-Casp-Out (50 µg), NGEmptyRRR (50 µg), NG-Casp-InRRR (50 µg) and NG-Casp-OutRRR (50 µg) were run on a
16% acrylamide gel under non-reducing conditions (no DTT present). Identical samples
were then treated with 100 mM DTT and allowed to sit at 25°C for one hour before SDSPAGE. Using a standard curve of known caspase concentrations the caspase released
from the nanogels was then quantified using the Bio-Rad Image LabTM software. This
yielded the precise amount of caspase released per 50 µg of nanogel.
2.4.8 Enzymatic degradation experiment
Sample solutions of nanogels and nanogel-caspase conjugates (1 mg/mL) with a final
volume of 0.050 mL were prepared. The concentration of caspase-3 in the conjugate
solutions was estimated to be 14 µM based on the feed amount during its synthesis
(caspase-3 molecular weight = 28,500). The protein was denatured by adding acetonitrile
(20% of the total volume) and the solutions were left at room temperature for 10 minutes.
The digestion of caspase-3 was performed by adding trypsin from porcine pancreas, 4:1
ratio (caspase-3:trypsin), and incubated for 20 hours at room temperature. Nanogels
solution was exposed to the same amounts and conditions as those for nanogel-caspase
conjugates.
The matrix solution was prepared by mixing 22.5 mg of α-cyano-hydroxycinnamic
acid in 350 µL tetrahydrofuran, 150 µL water and 6 µL of trifluoroacetic acid. 10 µL of
each of the sample solutions and 10 µL of the matrix solution were mixed and spotted on
a MALDI target.
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2.4.9. Activity Assay
For measurement of caspase-3 activity, milligrams of nanogel used was varied in
order to release 50 nM caspase-3 in each experiment. These nanogel-caspase conjugates
were incubated in 100 mM DTT for 1 hour in order to fully release the cargo caspase-3.
Identical samples were subject to 0.5 mM DTT treatment in an identical fashion in order
to assay for any free, or unbound, caspase-3. The caspase-3 activity was then assayed
over a 7 minute time course in caspase-3 activity assay buffer containing 20 mM HEPES
pH 7.5, 150 mM NaCl, 5 mM CaCl2, and 10% PEG 400. In this experiment, caspase-3
hydrolyzes the peptide substrate, N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin,
resulting in the release of the 7-amino-4-methylcoumarin (AMC) moiety as a fluorophore
that can be quantified over time. The fluorogenic substrate N-acetyl-Asp-Glu-Val-AspAMC, Enzo Lifesciences (Ac-DEVD-AMC), Ex 365/Em495, was added to a final
concentration of 100 µM to initiate the reaction. These 100 µL assays were performed in
duplicate in a 96-well microplate at 37°C using a spectramax M5 spectrophotometer.

Figure 2.11 Caspase-3 activity recovered after an
early protocol for the construction of caspasecontaining nanogels involving lyophilization. 50 nM
caspase-3 control and 50 nM released from nanogels.
	
  

52	
  

2.4.10. Cell Internalization Studies
Cell internalization studies were performed using Zeiss 510 META confocal laser
scanning microscopy. HeLa cells were cultured in T75 cell culture flask containing
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) with 10% fetal
bovine serum (FBS) supplement. The cells were seeded at 100,000 cells/mL in cover
slip-bottomed Petri dishes and allowed to grow for 1 day at 37°C in a 5% CO2 incubator.
The cells in 1 mL of culture medium were treated with nanogels and nanogel-FITCcaspase conjugates (0.5 mg/mL) and were incubated for 4 hours at 37°C before
monitoring the cells by confocal microscopy. The nucleus of the cells was stained by the
addition of DRAQ5 (5 µM). All images were taken using 63x oil immersion objectives
(excitation at 488 nm for FITC and 543 nm for DRAQ-5).

Figure 2.12 No cellular internalization after
incubating the cells for 4 hours with FITCcaspase-3. Within each image set, top left is the
FITC channel, which show green color for
caspase-3 and top right is the DRAQ5 channel,
which shows red color for the nucleus. Bottom
left is the DIC image and bottom right is the
overlap of all three.
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2.4.11. Apoptosis Studies
HeLa cells were cultured in T75 cell culture flasks using DMEM/F12 with 10% FBS
supplement. The cells were seeded at 10,000 cells/well/200 µL in a 96 well tissue culture
plate and allowed to grow for 24 hours under incubation at 37°C in 5% CO2. The cells
were then treated with different concentrations of nanogel-caspase conjugates and were
incubated for another 24 hours. Cell viability was measured using Alamar Blue assay
with each data point measured in triplicate. Fluorescence measurements were made
using the plate SpectraMax M5 by setting the excitation wavelength at 560 nm and
monitoring emission at 590 nm on a black 96 well flat bottom plate.

Figure 2.13 Apoptosis experiment performed with nanogel-caspaseRRR on day two.
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CHAPTER 3
TRI-FUNCTIONALIZATION OF AMINE-BASED SCAFFOLDS UTILIZING AN
EPISULFIDE MOIETY

3.1 Introduction
The development of new strategies for preparing materials endowed with multiple
functions has attracted attention in the field of nanotechnology with potential
implications in sensing,1–4 theranostics5–10 and biomedical applications11–13. Such
materials combining several functionalities can significantly enhance specificity and
capabilities within a single nanoscale construct. Significant efforts have been devoted to
the development of nanomaterials incorporating polyethylene glycol which adds
biological stealthiness thus improving stability in blood circulation,14,15 enhancing tissue
targeting, and

reducing toxicity.16–19 Simultaneously, the same nanoscaffold can be

modified with cell-penetrating moieties20–23 and imaging agents24,25 to monitor the drug
transport process. Although previous efforts have resulted in functionalized scaffolds
with promising properties the vast majority of examples in literature describe a bifunctionalization approach.
Scaffolds possessing both therapeutic and diagnostic capabilities have emerged as
potential candidates in theranostics.7–10 Typically, these materials lack targeting
capabilities, so introducing a targeting moiety as an additional functionality could
significantly improve the efficacy of these systems. However, incorporating three
functional molecules in one nanoplatform simultaneously is a rather challenging task. For
instance, typical strategies involve non-covalent interactions such as electrostatics26,27 and
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hydrophobic adsorptions28,29 however these systems do not enable absolute control over
the location or composition of the functional group within the scaffold. On the other
hand, covalent strategies offer better control over conjugation and quantification of
different functionalities. However, covalent attachment of guest molecules is more
specific towards particular reactive functional groups. Few reports describe the
preparation of tri-functional materials involving the covalent conjugation of imaging
agents, membrane translocation peptides, cell-targeting moieties and histidine-rich
peptides for lysosomal escape.20,23,24,30 These reports however, are considered trifunctional due to their therapeutic, imaging and cellular uptake capabilities in a single
particle. In most cases, these multi-functionalization capabilities rely on the topology or
architecture of the scaffold it self. For instance, mesoporous silica nanoparticles provide
three distinct domains (silica framework, pores/channels, surface), which can be
independently functionalized.23 However, there is difficulty in selectively combining
multiple functions within a single domain such as its surface. An advantage of multifunctionalizing the scaffold’s surface is that the core remains available for further
encapsulation or modification. Unfortunately, one of the present limitations with surface
functionalization is that the functional density is limited due to the lack of chemical
selectivity and functional groups. In this chapter, we describe a methodology for the
preparation of tri-functionalized materials with higher functional density, which hold
potential in multi-functionalization of scaffold surfaces.
3.2 Results and Discussion
Our approach is by using primary amines as the scaffold’s initial surface functional
group. Using amines is advantageous due to their high reactivity with a wide range of
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functional groups such as epoxides,31,32 activated esters,33,34 aldehydes,35 carboxylic
acids36,37, among others. The proposed methodology involves the use of an episulfidecontaining molecule as the initial functionality introduced due to its reactivity with
primary amines. The opening of the heterocyclic ring will lead to the development of a
new entity with nucleophilic character after the generation of a secondary amine and a
thiol group. A second functionality can be introduced utilizing a disulfide-containing
molecule to selectively couple with the free thiol generated. Due to the difference in
reactivity of the amine and free thiol, the first two functionalizations with the episulfide
opening and di-sulfide conjugation can be in theory be done in one step. Lastly, a reactive
compound such as an isothiocyanate molecule can then be introduced to react with the
remaining secondary amine.

In this design tetraethylene glycol monomethyl ether

episulfide was used as the first functionality to react with amine groups present on the
scaffold (Figure 3.1). Incorporating ethylene glycol moiety will introduce hydrophilicity
and biocompatibility to the system. This reaction will generate a secondary amine and a
thiol group to be used as handles for a second and third functionality.

Figure 3.1 Representation and chemical structures of the functionalities for the trifunctionalization process of amine-containing scaffolds.
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) also known as the Ellman’s reagent will
be used as the second functionality. The free thiol generated after reacting the amine and
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episulfide can selectively react with the Ellman’s reagent cleaving the disulfide bond and
releasing 2-nitro-5-thiobenzoic acid (TNB) (Scheme 3.1). Release of TNB can be

Scheme 3.1 Reaction of the 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) or Ellman’s
reagent with a thiol (R-SH).
quantified via absorption of visible light at 412 nm (Scheme 3.1) allowing for
quantification of di-sulfide conjugation onto the scaffold.38 The remaining secondary
amine generated will be then reacted with an isothiocyanate functional group.

In this

case fluorescein isothiocyanate was employed as the third functionality.
Among the different candidate scaffolds for surface functionalization, amphiphilic
polymeric nanoparticles are ideal due to their ability to encapsulate and release guest
molecules within their interior.39–41 Additionally, nanoparticles have high surface area
that could be utilized for multi-functionalization. However, their surface functionalization
capabilities are limited due to the lack of selective reactivity of functional groups. In
order to determine if this approach could be applicable to scaffolds with different
morphology and functional group density we were also interested in applying this
methodology to dendrimers. These scaffolds are considered exceptional nanomaterials
due to their unique properties including, hyper-branched globular shape, narrow
polydispersity index and control over molecular structure. Since dendrimers possess high
density of functional groups on their molecular surface, we were interested in examining
this approach in scaffolds where the conjugation could be challenging due to sterics.
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3.2.1 Scaffold Di-functionalization and Characterization
Polymeric nanoparticles previously reported in our group42 and PPI G4 dendrimers
were dispersed in sodium phosphate buffer pH 8. The one pot dual functionalization
reaction was carried after co-dispersing the nanoparticle (Scheme 3.2.A) and dendrimer
(Scheme 3.2.B) with the Ellman’s reagent. Triethylene glycol monomethyl ether
episulfide was then added slowly to the solution and the reaction mixture was allowed to
react at 50 oC for 22 hours.

	
  
Scheme 3.2 Di-functionalization reaction of the (A) nanoparticle (B) PPI G4
dendrimer.
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The progress of the di-functionalization reaction was monitored by the absorption of the
TNB released over time (Figure 3.2). After 3 to 4 hours the generation of TNB reached
saturation presumably due to the consumption of the episulfide-containing molecule. The
extent of functionalization was then quantified assuming that each Ellman’s reagent
attached is equivalent to the moles of episulfide conjugated onto the scaffold. Based on
the extinction coefficient of TNB, the amount of amine moieties from the nanoparticle
(Figure 3.2.A) that reacted with the episulfide-containing molecule and Ellman’s reagent
is 79%. The nanoparticles were prepared at pH 2 to allow the protonation of the amine
moieties.42 At this pH the polymer self-assembles in to an amphiphilic aggregate where
the amines groups are exposed towards the outside of the assembly. The core is then
crosslinked through photochemical reaction of the coumarin moieties. We believe that
this 79% conjugation corresponds to the percentages of amines accessible for conjugation
since some of these moieties might be buried in the interior of the nanoparticle. In the
case of the dendrimer (Figure 3.2.B) and based on the extinction coefficient of TNB,

Figure 3.2 Absorption spectra of TNB to monitor the progress of di-functionalization
reaction of (A) nanoparticle (B) dendrimer. The concentration used for the absorption
spectra was 0.1 mg/mL for the nanoparticle and 0.005 mg/mL for the dendrimer.
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100% of amines reacted and were conjugated to the tetraethylene glycol monomethyl
ether episulfide and Ellman’s reagent.
	
  	
  	
  	
  	
  After purification, the surface modification was evaluated by FTIR. The FTIR
spectrum of modified nanoparticles showed two distinct peaks around 1518 cm-1, 1338
cm-1 (Figure 3.3.A) and 1518 cm-1 and 1359 cm-1 (Figure 3.3.B) corresponding to the
stretching vibrations of N-O for both the nanoparticle and the dendrimer from the
Ellman’s reagent. To further confirm the di-functionalization reaction and considering the
deprotonated form of the carboxylic acid from the Ellman’s reagent at pH 7.4, we
evaluated the change in the surface charge by zeta potential measurements (Figure 3.3).
As expected, the surface charge of the nanoparticles before functionalization was found
to be 3.27 mV. In the case for the di-functionalized nanoparticle, the value shifted
towards -49.2 mV suggesting the conjugation of the Ellman’s reagent onto the surface of
the nanoparticles (Figure 3.3.C). Similarly, the surface charge reflects a value of 7.5 mV
for non-modified dendrimer whereas the value observed for di-functionalized dendrimer
shifted towards negative values, -18.1 mV (Figure 3.3D).
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Figure 3.3 FTIR spectra of di-functionalized (A) nanoparticle and (B) PPI G4 dendrimer.
Zeta potential measurements for (C) nanoparticle and (D) PPI G4 dendrimer.

3.2.2 Scaffold Tri-functionalization and Characterization
Secondary amines are known to be reactive with isothiocyanate groups.43,44 To
evaluate if this amine could be used as a handle to attach a third functionality we utilized
fluorescein isothiocyanate (FITC). An excess amount of FITC was added and the reaction
mixture and allowed to react overnight at room temperature (Scheme 3.3). After
dialyzing out excess FITC conjugation thiourea stretches were confirmed via FTIR for
tri-functionalized scaffolds (Figure 3.4). The C=S vibrations were observed in the case of
the nanoparticle (Figure 3.4.A) around 1165 cm-1 and 1212 cm-1 for the dendrimer
(Figure 3.4.B).

	
  

66	
  

Figure 3.4 FTIR spectra of tri-functionalized (A) nanoparticle (B) PPI G4 dendrimer.
	
  
To further confirm the conjugation of FITC we took the absorption spectra of the trifunctionalized nanoparticle (Figure 3.5.A) and dendrimer (Figure 3.5.B). As predicted, a
peak around 495 nm was observed corresponding to the maximum absorption of FITC.
In addition, a peak around 350 nm is observed corresponding to the half of the Ellman’s
reagent molecule attached to the scaffold. Based on this graph we can also determine that
for the case of the nanoparticle the ratio between conjugated half Ellman’s reagent and
FITC is about 1: 0.8. Similarly for PPI G4 dendrimer, the ratio for conjugated half
Ellman’s reagent and FITC is 0.7 : 1.

Figure 3.5. Absorption spectra of tri-functionalized (A) nanoparticle (B) PPI G4
dendrimer. The concentration was 1 mg/mL for nanoparticle and 0.05 mg/mL for
dendrimer.
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3.3 Summary
In this chapter we report a straightforward methodology for the preparation of trifunctionalized amine materials with high functional density is presented. Our approach is
based in the use of an episulfide-containing molecule being the first functionality
introduced due to its reactivity with primary amines causing the generation of a
secondary amine and free thiol group. The second molecule introduced will have a
disulfide to selectively couple with the free thiol generated. Lastly a reactive compound
such as isothiocyanate molecule will be introduced to react with the remaining secondary
amine. This approach can be applied to construct multifunctional nanoscaffolds with high
surface functionality for potential in biomedical applications.
3.4 Experimental Details
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), tetraethylene glycol monomethyl ether,
epichlorohydrin, PPI G4 dendrimer, epichlorohydrin, sodium hydride, sodium
thiocyanate, and fluorescein isothiocyanate were obtained from commercial sources and
used without further purification. Polymeric nanogel was prepared using the previously
reported procedure. (ACS Macro Lett. 2013, 2, 948-951). 1H-NMR spectra were recorded
on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of the
solvent as the internal standard. Chemical shifts are reported in parts per million (ppm).
Dynamic ligth scattering (DLS) and zeta potential measurements were performed using a
Malvern Instrument Nanozetasizer. UV-Visible absorption spectra were recorded on a
Varian (Model EL 01125047) spectrophotometer.

The fluorescence spectra were

obtained from a JASCO FP-6500 spectrofluorimeter. FTIR spectra were recorded on a
Perkin Elmer spectrometer.
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3.4.1 Synthetic Protocols and Characterization for Compounds
Synthesis of the Triethylene Glycol Monomethyl Ether Episulfide:

O
O

OH
3

Cl

NaH, DMF

O
O

O
3

S

NaSCN (aq)
55%

O

O
3

38%

Scheme 3.3 Synthesis of the triethylene glycol monomethyl ether episulfide.
Synthesis of (±)-(2,5,8,11-tetraoxadodecyl)oxirane:
To a solution of triethylene glycol monomethyl ether (20 mL, 125 mmol) in THF (125
mL) was added NaH (9g, 60% in mineral oil). Mixture stirred for 2 h. at rt before slowly
adding epichlorohydrin (39 mL, 500 mmol). The reaction mixture was stirred at rt for 13
h. before filtering through celite and concentrated in vacuo to give a yellow oil. (J. Am.
Chem. Soc. 2011, 133, 14260-14263) The crude product was purified by silica gel flash
chromatography eluting up to 10 % MeOH/DCM yielding a clear oil (16.2 g, 74 mmol,
59%). 1H NMR (400 MHz, CDCl3) δ 3.76 (m, 1H), 3.64 (m, 10H), 3.52 (m, 2H), 3.38 (m,
1H), 3.34 (s, 3H), 3.13 (m, 1H), 2.76 (m, 1H), 2.58 (m, 1H) 13C NMR (100 MHz, CDCl3)
δ 71.98, 71.92, 70.7, 70.6 (overlapping peaks), 70.5, 59.0, 50.8, 44.3.
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Figure 3.6 1H NMR (A) and 13C NMR (B) of the (±)-(2,5,8,11tetraoxadodecyl)oxirane or the triethylene glycol mono methyl ether epoxide.
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Synthesis of (±)-(2,5,8,11-tetraoxadodecyl)episulfide:
To (±)-(2,5,8,11-tetraoxadodecyl)oxirane (2.0g, 9.1 mmol) was added aqueous
NaSCN (20 mL, 1M). The reaction was stirred at room temperature for 24 hours before
diluting in water and extensively washing with ether. Organic layers were dried over
MgSO4, filtered, and concentrated in vacuo. (Org. Biomol. Chem. 2009, 7, 1397–1403).
The crude product was purified via silica gel flash chromatography eluting up to 10%
MeOH/ DCM to afford a clear oil (1.2 g, 55 %) 1H NMR (400 MHz, CDCl3) δ 3.62 (m,
11H), 3.54 (m, 2H), 3.48 (dd, J = 10.8, 6.84 Hz, 1H), 3.37 (s, 3H), 3.08 (m, 1H), 2.51 (dt,
J = 6.20, 1.0 Hz, 1H), 2.21 (dd, J = 5.38, 1.26 Hz, 1H)

13

C NMR (100 MHz, CDCl3) δ

75.9, 72.0, 70.6 (overlapping peaks), 70.5, 70.4, 59.1, 32.1, 23.9; HRMS (ESI) calcd. for
C10H20O4S (M+Na) 259.0957, found 259.0983.
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Figure 3.7 1H NMR (A) and 13C NMR (B) of the (±)-(2,5,8,11tetraoxadodecyl)episulfide or the triethylene glycol mono methyl ether episulfide.
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Synthesis of the N-2-[(tert-butoxycarbonyl)amino] ethyl methacrylamide (BocAEMA)-co-4-methylcoumarin-7-oxypropyl methacrylamide (CPMA) random
copolymer:
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O
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O
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O
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O

O

O

O

Scheme 3.4 Synthesis of the Boc-AEMA-co-CPMA random copolymer.
The boc-protected random co polymer was synthesized according to the previously
reported procedure via RAFT polymerization (ACS Macro Lett. 2013, 2, 948–951). 1H
NMR (400 MHz, CDCl3) δ 7.3-7.4, 6.5-6.9, 5.9-6.1, 3.9-4.1, 3.0-3.4, 2.1-2.4, 1.9-2.0,

Figure 3.8 1H NMR spectrum of the Boc-AEMA-co-CPMA. Methyl proton signals of
the Boc group at 1.3-1.4 ppm.
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1.7-1.8, 1.3-1.4, 0.9-1.2
Synthesis of the de-protected AEMA-co-CPMA random co-polymer:
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Scheme 3.5 Boc-deprotection of the AEMA-coCPMA random copolymer

The deprotection reaction and purification was carried out as previously reported. (ACS
Macro Lett. 2013, 2, 948–951). 1H NMR (400 MHz, DMSO-d6) δ 7.8-8.0, 7.3-7.7, 6.76.9, 6.0-6.2, 3.9-4.1, 3.0-3.2, 2.80-2.84, 2.2-2.4, 1.6-1.9, 0.7-1.0
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Figure 3.9 1H NMR spectrum of the deprotected AEMA-co-CPMA.

3.4.2 Control Experiment: Ellman’s reagent exposed to pH 8.
Ellman’s reagent was exposed to sodium phosphate buffer pH 8 and the absorption
spectra were recorded over a period of 22 hours. The reagent is stable over this period of
time. Ellman’s reagent was broken releasing the TNB after exposing it to pH 10.

	
  

Figure 3.10 Absorption spectra of Ellman's reagent exposed to pH 8 for up to 20
hours indicating the stability of this reagent75	
  
at this pH.

3.4.3 Control Experiment: Ellman’s reagent exposed to 50 oC.
Ellman’s reagent was dissolved in sodium phosphate pH 8 buffer and and placed in a
snad bath at 50 oC for 18 hours. Ellman’s reagent is stable under these conditions.

Figure 3.11 Ellman’s reagent in sodium phosphate pH 8
buffer at 50 oC.
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CHAPTER 4
EFFECT OF PARTITION COEFFICIENT IN DRUG LOADING AND
ENCAPSULATION EFFICIENCY IN POLYMERIC NANOGELS

4.1 Introduction
Polymeric nanoparticles have attracted attention as delivery systems due to their
ability to sequester, transport and selectively release hydrophobic guest molecules under
certain stimuli conditions.1–5 A critical factor for an efficient delivery vehicle is the
capacity to stably encapsulate guest molecules to prevent drug leakage during circulation
thus reducing unwanted toxicity. Therefore, an understanding of the dynamics of guest
exchange with the bulk media is imperative. Our group recently reported the
development of a fluorescence resonance energy transfer (FRET) based assay to evaluate
the encapsulation stability of polymeric nanogels in aqueous media.6 In this method a
lipophilic FRET pair 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate
(DiI, acceptor) and 3,3’-dioctadecyloxacarbocyanine perchlorate (DiO, donor) were
independently encapsulated in polymeric nanogels. When these solutions are mixed two
limiting scenarios are possible (Figure 4.1).
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Figure 4.1 Potential FRET outcomes upon mixing nanogels independently encapsulating
DiI and DiO.

If the dyes are stably encapsulated within the polymeric nanogels, the guest molecules
will not exchange with the bulk solvent and will remain in their original container. In this
case there will be no FRET observed because the distance between these two pairs will
exceed their Förster radius. On the other hand, if the lipophilic molecules exchange
between the container interior and the bulk solvent, the dyes will equilibrate between the
two containers, occupying the same nanogel leading to increased FRET. Thus,
monitoring the evolution of FRET over time provides us with insight into the exchange
dynamics with the bulk environment and the stability of guest encapsulation. Utilizing
this methodology, our group has also investigated the encapsulation stability of guest
molecules in an environment that mimics cells by utilizing dioleoyl phosphatidylcholine
(DOPC) bilayer vesicles.7 We have also studied the effect of scaffold hydrophobicity in
drug loading and encapsulation with this methodology.8 However, DiO and DiI are
highly lipophilic molecules with a partition coefficient (log P) value greater than 10.9
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(Molinspiration Property Calculation Service (www.molinspiration.com) On the other
hand, the log P values of drug molecules available to treat diseases rely on values lower
than 10 (Table 4.1).

Table 4.1 Partition coefficient (log P) value for some drug molecules.
Drug

Log P

Uses

Docetaxel

4.2610

Anticancer

Doxorubicin

1.311

Anticancer

Paclitaxel

3.9612

Anticancer

Dexamethasone

1.7913

Anti-inflammatory and immunosuppressant

Phenytoin

2.1413

Convulsion and seizures

Diazepam

2.9813

Anxiety and panic attacks

Cisplatin

2.3514

Anticancer

Mannitol

-3.1015

Osmotherapy, head trauma cranial pressure

Therefore, if we were to use these nanogels as potential delivery vehicles it is crucial to
understand the effect of the dye’s hydrophobicity on the dynamics of guest exchange. In
this chapter, we study the effect of the log P value of guest molecules on the
encapsulation efficiency and ultimately the loading capacity.
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4.2 Molecular Design and Results
Our approach is to utilize our polymeric nanogels and encapsulate FRET partner dyes
with different lipophilicities. Also, we were interested in understanding the role of drug
loading and crosslinking density in encapsulation stability. Our goal is to encapsulate 0.5,
2 and 10 weight percent (wt%) of each dye. The crosslinking density will be varied
having non-crosslinked polymer aggregates and 100% crosslinked nanogels as controls.
We chose our PEG:PDS polymeric nanogels as the target scaffold with a ratio of 26%
PEG and 74% as discerned by NMR (polymer synthesis and NMR by Mallory Gordon).
Nanogels were synthesized by exposing the polymer to an aqueous solution and the selfcrosslinking process was enabled by intra- and inter-chain disulfide cross-linking of the
PDS groups in the presence of the reducing agent dithiothreitol (DTT) (Figure 4.2A).
FRET pairs were chosen according to their predicted Log P value obtained from the
Molinspiration Interactive Log P calculator (Figure 4.2B and 4.3). This property
calculator service was validated by comparing predicted values of different molecules
with their corresponding experimental Log P found in literature (Table 4.2). In this
project, we will use naphthalene/N-dansyl ethylamine, pyrene/perylene and DiO/DiI for a
Log P value of ~3, 5 and 10, respectively.
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Figure 4.2 (A) Synthesis of the nanogels intra- and inter-chain disulfide cross-linking of
the PDS groups in the presence of the reducing agent DTT (B) Molinspiration Interactive
Log P calculator

Figure 4.3 Chemical structures of the FRET pairs from each Log P value studied. Log P
values were predicted using the Molinspiration Interactive Log P calculator.
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Table 4.2 Validation of the Molinspiration Software with Literature Values.
Compound

Literature log P Value

	
  
	
  

Predicted log P Value
Molinspiration Software

Aspirin

1.1416

1.87

Salicylamide

1.2817

1.20

Naphthalene

3.3418

3.10

Anthracene

4.5018

4.30

Benzene

2.1319

1.90

4.2.1 Pyrene and Perylene Spectral Overlap and Nanogel Sizes
We started our experiments utilizing pyrene and perylene since these dyes were readily
available in our lab. In order for FRET to occur the absorption spectrum of the acceptor,
in this case perylene, must overlap with the fluorescence emission spectrum of pyrene,
the donor. To evaluate if these dyes meet this requirement, we prepared solutions with
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0.005 mg/mL of pyrene and perylene in dimethyl sulfoxide and the emission and
absorption spectra were recorded (Figure 4.4B). Then, we proceeded with the synthesis
of the polymeric nanogels encapsulating 0.5 wt% pyrene and perylene by in situ loading.
The size of the resulting nanogels encapsulating pyrene was evaluated by dynamic light

Figure 4.4 (A) Absorption spectra of pyrene and perylene (B) Overlap spectra of FRET
pairs pyrene and perylene. Samples prepared at a concentration of 0.005 mg/mL in
dimethyl sulfoxide.
scattering (DLS) and found to be 21, 18 and 15 nm for 5, 12 and 100 % crosslinked
nanogels, respectively (Figure 4.5A). The size slightly decreased as the crosslinking
density increased. On the other hand, the size for nanogels encapsulating perylene
increased from 13, 15 and 28 nm as the crosslinking density increased (Figure 4.5B).
These differences could be attributed to the packing of each dye within the nanogels.
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Figure 4.5 Dynamic light scattering of 0.1 mg/mL aqueous solution of nanogels
encapsulating (A) pyrene and (B) perylene.

4.2.2 Encapsulation Efficiency Evaluation
In order to evaluate their encapsulation efficiency, we calculated the dye loading
amounts of dye for each sample based on the recorded absorbance values of the purified
nanogels. Since the pyrene monomer fluorescence shows strong solvent dependence we
evaluated the environment polarity of encapsulated pyrene. For this, the emission
spectrum of 5% crosslinked nanogels encapsulating pyrene was recorded and normalized
with reference to the I1 peak (Figure 4.6A). Since the I3 peak shows maximum variations
in intensity relative to I1 peak, the intensity of I3/I1 will be used to determine the
environmental effects on pyrene fluorescence by comparing with relative peak intensities
for the five principal vibronic bands in various solvents.20 Based on this analysis it was
determined that the relative intensity of pyrene monomer fluorescence matched that
observed in chloroform (CHCl3).

Therefore the absorption spectra of different

concentrations of pyrene and perylene in CHCl3 were recorded (Figure 4.6B).
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Figure 4.6 (A) Normalized emission spectrum of 5% crosslinked nanogels
encapsulating 0.5 wt% pyrene. Concentration of the sample was 0.1 mg/mL (B)
Absorption spectra of different concentrations of pyrene and perylene in chloroform.

A calibration curve was prepared for pyrene (Figure 4.7A) and perylene (Figure 4.7B)
and the extinction coefficients were found to be 28047 M-1cm-1 and 27120 M-1cm-1,
respectively. After removing the excess dye and by-products of the crosslinking reaction
by dialysis, guest encapsulation in these nanogels was measured by UV-visible
spectroscopy. The absorption spectra of nanogels loading pyrene (Figure 4.7C) and
perylene (Figure 4.7D) was recorded in order to calculate the extent of guest loading. As
observed in Table 3A, the encapsulation for pyrene was 100% efficient independently of
the crosslinking density of the nanogels whereas for perylene this was not the case. The
highest loading was achieved by polymer aggregates with 34% efficiency whereas the
lowest encapsulation (11%) was observed for nanogels with 100% crosslink density.
This difference can be attributed possibly to the influence of perylene π- π interactions
which could affect the self-assembly of the polymer and thus loading. The amount of
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perylene fed into the polymer solution was increased up to 0.15 mg but after purification
the encapsulation efficiency didn’t increase significantly (Table 4.3B).

Figure 4.7 Calibration curve of (A) pyrene and (B) perylene in CHCl3 prepared to
determine the extinction coefficient for each dyes. Absorption spectra recorded of
nanogels (0.1 mg/mL) with different crosslinking densities loading 0.5 wt% (C)
pyrene and (D) perylene.

After evaluating the loading efficiency of these dyes, we were then interested in
investigating the encapsulation capabilities of nanogels with this pair of dyes possessing a
log P value between 5.2 – 5.8. We utilized a FRET-based assay for which nanogel
samples encapsulating pyrene were mixed with those containing encapsulated perylene
with both nanogels having equal concentrations of 0.1 mg/mL in the resulting mixture.
The time-dependent FRET evolution along with the absorption spectra of the mixed
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nanogel solutions is plotted in Figure 4.8. As observed in this figure, nanogels 0% and
100% crosslinked (Figure 4.8A and D) exhibited faster FRET rates over a period of 6
hours with a rapid burst of FRET within the first 90 minutes. On the other hand 5%
crosslinked nanogels (Figure 4.8B) displayed the steadiest FRET evolution suggesting
that this crosslinking density provides the most stable encapsulation. Nanogels 15%
crosslinked (Figure 4.8C) showed the most fluctuations in FRET especially during the
first 2 hours. However, it is important to note the difference in the loading amount of
perylene. This variable could potentially influence the dye exchanges.

Table 4.3 Summary of the percentage of crosslinking density and encapsulation
efficiencies.
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Figure 4.8 FRET evolution spectra of nanogels (A) 0% (B) 5% (C) 15% (D) 100%
crosslinked. Absorption spectra of nanogels (E) 0% (F) 5% (G) 15% (H) 100%
crosslinked. These measurements were taken at a concentration of 0.1 mg/mL.
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4.3 Summary
In this chapter we utilized our redox-sensitive polymeric nanogels composed of
oligo(ethylene glycol) methacrylate and pyridyldisulfide methacrylate to investigate the
effect that the guest molecule’s lipophilicity has with respect to the encapsulation
efficiency. We utilized a variety of guest molecules with different partition coefficient
values (log P). We were able to prepare nanogels encapsulating pyrene and peylene
(predicted log P 5.2 – 5.8) with different crosslinking densities. At this log P range, the
encapsulation of pyrene was significantly more efficient than was observed for perylene.
Preliminary FRET based experiments show that slightly (5%) crosslinked nanogels
provide the more stable encapsulation of guest molecules possessing this log P value.
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CHAPTER 5
SUMMARY AND FUTURE DIRECTIONS

5.1 Summary
Nanoparticles have recently emerged as potential candidates for use as carriers in
delivery applications, theranostics, and sensing among others. While nanoparticles can
be prepared from metals and inorganic materials, polymeric nanoparticles allow noncovalent guest encapsulation and surface functionalization. Additionally, their structure
can be modified to achieve biocompatible materials. In this dissertation, we focus our
work on the use of amphiphilic random copolymers and their tendency to self-assembly
in aqueous solution. These micellar aggregates are then converted into nanoparticles in
one step without the need for further modifications.
In Chapter 1, we discussed the characteristics or requirements that a nanoparticle must
possess to be utilized as a carrier for biomolecules and drugs. In Chapter 2, we studied
the use of PEG-PDS polymeric nanogels for “locking-in” the structure of a protein by
polymer conjugation, simultaneously protecting its delicate folded state and silencing its
enzymatic activity. This method also allows recovery of activity only upon cytosolic
uptake, which triggers the release from the polymer. The release of the apoptotic protein
was assessed through enzymatic activity and cell viability assays. In Chapter 3, we
describe a straightforward methodology for the preparation of tri-functionalized amine
materials with high functional density. We targeted primary amines as the scaffold’s
surface functional group to couple with three different molecules; an episulfidecontaining molecule, Ellman’s reagent and fluorescein isothiocyanate. In Chapter 4 we
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introduced a new project that was started in July of 2014 with the main objective of
investigating the effect that the guest molecule’s lipophilicity has with respect to the
encapsulation efficiency of nanogels. Although pyrene and perylene were encapsulated
into the PEG-PDS polymeric, we observed poor encapsulation efficiency for perylene
compared to pyrene.

5.2 Future Directions
In Chapter 2 we were able to demonstrate the successful conjugation of caspase-3 on
either the interior or the surface of nanogels by a thiol-disulfide exchange reaction
between unreacted polymer PDS groups and surface exposed cysteine residues in the
protein. However, it would be useful to determine the amount of protein per nanogel
particle. Although nanogels lacking cell-penetrating peptides showed less cell
internalization than the RRR nanogels, these nanogels were more efficient at inducing
cell death. Therefore, it would be useful to identify the cell internalization mechanism in
order to determine if these nanogels are in fact becoming entrapped in endosomes. We
utilized RRR peptide as a proof-of-concept but it would be beneficial to utilize a more
biologically relevant and/or neutral ligand to avoid charge interference with
internalization.
In Chapter 3 we describe a methodology to tri-functionalize amine-containing
polymeric materials.

Our approach is based on the use of an episulfide-containing

molecule, as the first functionality introduced due to its reactivity with primary amines
causing the generation of a secondary amine and thiol group. The second molecule
introduced will have a disulfide to selectively couple with the free thiol generated. Lastly
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a reactive compound such as isothiocyanate molecule is introduced to react with the
remaining secondary amine. Pre-eliminary findings in our group suggest that a small
percentage of amines could react with disulfides. For this methodology to be effective
and in high yields we need to make sure that there is no side-reaction occurring between
the amine-containing scaffold and the Ellman’s reagent. Therefore, we should monitor
the absorption spectra over time of Ellman’s reagent in the presence of the nanoparticle
and/or PPI dendrimer at pH 8. This experiment should be carried out at the same
concentration we utilized to monitor the di-functionalization reaction (~0.1 mg/mL). In
addition, we should apply this methodology to other scaffolds including polymer and
metal-nanoparticles. As a proof-of-concept we utilized tri-ethylene glycol, Ellman’s
reagent and fluorescein isothiocyanate but this work could have potential implication in
theranostics applications if we utilize for example an episulfide-containing drug
molecule, a targeting antibody /ligand and a Near Infrared Light (NIR) dye molecule.
In Chapter 4 we were able to encapsulate pyrene and perylene into PEG-PDS
polymeric nanogels.

However the encapsulation efficiency was poor for perylene

possibly due to stronger π-π interactions. Therefore, for this log P range (~5) we should
utilize Cy3 and Cy5 since the log P value of these dyes falls within this range and will
eliminate any complications due to π-π stacking.
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